CA982479A - Polylactide-drug mixtures - Google Patents

Polylactide-drug mixtures

Info

Publication number
CA982479A
CA982479A CA096,095A CA96095A CA982479A CA 982479 A CA982479 A CA 982479A CA 96095 A CA96095 A CA 96095A CA 982479 A CA982479 A CA 982479A
Authority
CA
Canada
Prior art keywords
polylactide
drug mixtures
drug
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA096,095A
Other languages
English (en)
Other versions
CA96095S (en
Inventor
George A. Boswell (Jr.)
Richard M. Scribner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Application granted granted Critical
Publication of CA982479A publication Critical patent/CA982479A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA096,095A 1969-10-23 1970-10-20 Polylactide-drug mixtures Expired CA982479A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86889969A 1969-10-23 1969-10-23
US7930970A 1970-10-08 1970-10-08

Publications (1)

Publication Number Publication Date
CA982479A true CA982479A (en) 1976-01-27

Family

ID=26761845

Family Applications (1)

Application Number Title Priority Date Filing Date
CA096,095A Expired CA982479A (en) 1969-10-23 1970-10-20 Polylactide-drug mixtures

Country Status (6)

Country Link
US (1) US3773919A (Direct)
JP (1) JPS5017525B1 (Direct)
CA (1) CA982479A (Direct)
DE (1) DE2051580C3 (Direct)
FR (1) FR2070153B1 (Direct)
GB (1) GB1325209A (Direct)

Families Citing this family (2602)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
BE793246A (fr) * 1971-12-30 1973-06-22 Xerox Corp Procede d'encapsulation
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3991766A (en) * 1973-05-31 1976-11-16 American Cyanamid Company Controlled release of medicaments using polymers from glycolic acid
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4054138A (en) * 1974-12-30 1977-10-18 Louis Bucalo Implants for acting on living beings
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
US4076798A (en) * 1975-05-29 1978-02-28 American Cyanamid Company High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4115544A (en) * 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
HU174057B (hu) * 1976-09-17 1979-10-28 Richter Gedeon Vegyeszet Sostav dlja pokrytij obespechivajuhhij uregulirovannuju otdachy aktivnogo vehhestva biologicheski aktivnykh preparatov i sposob poluchenija takikh preparatov s uregulirovannoj otdachej aktivnogo vehhestva
US4328204A (en) * 1977-03-02 1982-05-04 Ethicon, Inc. Absorbable polymer-drug compounds and method for making same
DE2856901D2 (de) * 1977-06-07 1980-11-13 Garching Instrumente Form of implant medicament and preparation process
CH644768A5 (de) * 1977-08-25 1984-08-31 Sandoz Ag Verfahren zur herstellung von mikrokugeln.
US4186189A (en) * 1977-09-28 1980-01-29 Ethicon, Inc. Absorbable pharmaceutical compositions based on poly(alkylene oxalates)
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
US4159322A (en) * 1978-06-26 1979-06-26 A. H. Robins Company, Inc. Anticoccidium implants
GB2026862A (en) * 1978-08-04 1980-02-13 Robins Co Inc A H Filaricide implants containing diethylcarbamazine
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
CA1143289A (en) * 1978-10-17 1983-03-22 Lee R. Beck Microparticle drug delivery system
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
AR221964A1 (es) * 1979-09-12 1981-03-31 Lilly Co Eli Dispositivo para rumiantes
NZ194900A (en) * 1979-09-12 1983-04-12 Lilly Co Eli Controlled release growth promoting formulations
US4333919A (en) * 1979-09-12 1982-06-08 Eli Lilly And Company Growth promotant controlled release formulations and method of treatment
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
GB2091554B (en) * 1981-01-13 1984-09-12 Mitsui Toatsu Chemicals Rod like moulded drug
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
EP0086627B1 (en) * 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
WO1983003061A1 (en) * 1982-03-04 1983-09-15 Battelle Development Corp Dual microcapsules
US4532123A (en) * 1982-03-04 1985-07-30 Battelle Development Corporation Dual Microcapsules and process for their preparation
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
DE3218151A1 (de) * 1982-05-14 1983-11-17 Akzo Gmbh, 5600 Wuppertal Mikroporoese, pulverfoermige polylactide und verfahren zu deren herstellung
DE3218150C2 (de) * 1982-05-14 1986-09-25 Akzo Gmbh, 5600 Wuppertal Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
US5248700A (en) * 1982-05-14 1993-09-28 Akzo Nv Active agent containing solid structures for prolonged release of active agents
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
AT382076B (de) * 1982-10-15 1987-01-12 Chemie Linz Ag Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
US4523591A (en) * 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4550449A (en) * 1982-11-08 1985-11-05 Johnson & Johnson Products Inc. Absorbable bone fixation device
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
FR2557459B1 (fr) * 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
US4578384A (en) * 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
ATE142236T1 (de) * 1984-03-06 1996-09-15 United States Surgical Corp Ein verfahren zur herstellung von zwei-phasen- zusammensetzungen für absorbierbare chirurgische ausrüstungen
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US4659693A (en) * 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
DE3428640A1 (de) * 1984-08-03 1986-02-06 Akzo Gmbh, 5600 Wuppertal Mikroporoese, pulverfoermige polylactide
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
EP0245840B1 (de) * 1986-05-15 1993-12-01 Hoechst Aktiengesellschaft Biologisch abbaubare Polymere für Depotzubereitungen mit kontrollierter Wirkstoffabgabe
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4744365A (en) * 1986-07-17 1988-05-17 United States Surgical Corporation Two-phase compositions for absorbable surgical devices
US4758435A (en) * 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3700128A1 (de) * 1987-01-03 1988-07-14 Hoechst Ag Biologisch abbaubare poly- (hydroxyalkyl)- aminodicarbonsaeure-derivate, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
DE3701625A1 (de) * 1987-01-21 1988-08-04 Boehringer Ingelheim Kg Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
DE3712095A1 (de) * 1987-04-10 1988-10-20 Lentia Gmbh Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
FR2618674B1 (fr) * 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
AU2810189A (en) * 1987-10-30 1989-05-23 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
EP0480918A1 (en) 1988-02-10 1992-04-22 Abbott Laboratories Reduced size lhrh analogs
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
DE3826915A1 (de) * 1988-08-09 1990-02-15 Henkel Kgaa Neue werkstoffe fuer den knochenersatz und knochen- bzw. prothesenverbund
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6797270B1 (en) * 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US5491131A (en) * 1989-04-14 1996-02-13 Applied Research Systems Ars Holding Nv Somatostatin-active polypeptide composition
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5232707A (en) * 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5268178A (en) * 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
DE59003337D1 (de) * 1989-10-16 1993-12-09 Danubia Petrochem Polymere Pressling mit retardierter Wirkstofffreisetzung.
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4002736A1 (de) * 1990-01-31 1991-08-01 Hoechst Ag Biologisch abbaubare polymere, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
US6228954B1 (en) 1991-02-12 2001-05-08 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom
US5320624A (en) * 1991-02-12 1994-06-14 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom
US5153002A (en) * 1991-03-04 1992-10-06 University Of Montreal Biocompatible gradient controlled release implant
WO1992019263A1 (en) 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
EP0514790A2 (de) * 1991-05-24 1992-11-25 Hoechst Aktiengesellschaft Polykondensate, die Weinsäurederivate enthalten, Verfahren zu ihrer Herstellung und Verwendung derselben
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
AU2572692A (en) 1991-09-09 1993-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and devices for treating hemophilia and aids
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6005067A (en) 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
FR2689400B1 (fr) * 1992-04-03 1995-06-23 Inoteb Materiau pour prothese osseuse contenant des particules de carbonate de calcium dispersees dans une matrice polymere bioresorbable.
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
DE69327495T2 (de) * 1992-07-13 2000-06-15 Nisshin Flour Milling Co., Ltd. Arzneimittel die Glicentin als aktiven Wirkstoff enthalten
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US6005068A (en) 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
ATE173520T1 (de) * 1992-10-02 1998-12-15 Cargill Inc Papier mit einer beschichtung aus schmelzstabilem polymer und dessen verfahren zur herstellung
JP3447289B2 (ja) * 1992-10-02 2003-09-16 カーギル， インコーポレイテッド 溶融安定性ラクチドポリマー繊維及びその製造方法
DE69327542T2 (de) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6387363B1 (en) 1992-12-31 2002-05-14 United States Surgical Corporation Biocompatible medical devices
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2114290C (en) * 1993-01-27 2006-01-10 Nagabushanam Totakura Post-surgical anti-adhesion device
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6495343B1 (en) 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6638905B2 (en) * 1993-06-18 2003-10-28 The Salk Institute For Biological Studies Cloning and recombinant production of CFR receptor(s)
EP0706374B1 (en) * 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
JP3822232B2 (ja) 1993-08-30 2006-09-13 ベイラー・カレッジ・オブ・メディシン 老化細胞由来ｄｎａ合成阻害因子
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JP3841309B2 (ja) * 1993-10-22 2006-11-01 ジェネンテック・インコーポレーテッド 流動床乾燥工程を含んでなるミクロスフェアの製造方法
US5339766A (en) 1993-11-03 1994-08-23 Embrex, Inc. Method of introducing material into eggs during early embryonic development
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
DE4406172C2 (de) * 1994-02-25 2003-10-02 Sanol Arznei Schwarz Gmbh Polyester
DE4407898A1 (de) * 1994-03-09 1995-09-14 Hoechst Ag Nanopartikel, enthaltend einen Wirkstoff und ein Polyketalweinsäureamid, Verfahren zu ihrer Herstellung und Verwendung derselben
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
JPH09511666A (ja) * 1994-04-08 1997-11-25 アトリックス・ラボラトリーズ・インコーポレイテッド 医療装置で使用する付随的ポリマー系
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US6339130B1 (en) * 1994-07-22 2002-01-15 United States Surgical Corporation Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US5578662A (en) 1994-07-22 1996-11-26 United States Surgical Corporation Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US5660817A (en) * 1994-11-09 1997-08-26 Gillette Canada, Inc. Desensitizing teeth with degradable particles
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
RU2161502C2 (ru) * 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
US5641502A (en) * 1995-06-07 1997-06-24 United States Surgical Corporation Biodegradable moldable surgical material
WO1996041616A1 (en) 1995-06-09 1996-12-27 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
DE19537415A1 (de) * 1995-10-09 1997-04-10 New Standard Gmbh Micro Wirkstoff-Perlen
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6004572A (en) * 1996-01-25 1999-12-21 Triangle Laboratories, Inc. Time release delivery system
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
RU2165942C2 (ru) * 1996-04-23 2001-04-27 Кинертон Лимитид Биоразрушаемый сложный полиэфир и способ его получения (варианты)
FR2748205A1 (fr) 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
CA2260750C (en) 1996-06-24 2004-11-09 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US5756651A (en) * 1996-07-17 1998-05-26 Chronopol, Inc. Impact modified polylactide
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
EP1577391A1 (en) 1996-10-25 2005-09-21 Human Genome Sciences, Inc. Neutrokine alpha
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
WO2001040466A2 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) * 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
DE69838061T2 (de) * 1997-04-18 2008-03-13 Biogen Idec Ma Inc., Cambridge Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
CA2291221A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. 32 human secreted proteins
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
FR2764514B1 (fr) * 1997-06-13 1999-09-03 Biopharmex Holding Sa Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DE69841140D1 (de) 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
IL135704A (en) 1997-10-29 2008-04-13 Genentech Inc Method of diagnosing neoplastic cell growth by detection of the wnt-1 induced secreted polypeptide wisp-1
IL135607A0 (en) 1997-10-29 2001-05-20 Genentech Inc Wnt-1 inducible genes
ATE233097T1 (de) 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
DE69840105D1 (de) 1997-11-21 2008-11-20 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
JP2001524308A (ja) * 1997-11-21 2001-12-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ケモカインα−５
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
KR19990065921A (ko) * 1998-01-19 1999-08-16 김충섭 항생제의서방성제제
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
DE69939374D1 (de) 1998-03-17 2008-10-02 Genentech Inc Zu vegf und bmp1 homologe polypeptide
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US7700353B2 (en) * 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
ES2267294T3 (es) * 1998-10-09 2007-03-01 Biogen Idec Ma Inc. Reversion del choque generalizado inducido por virus y de la disnea mediante el bloqueo de la ruta de la linfotoxina beta.
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
US20030099682A1 (en) * 1998-11-20 2003-05-29 Francis Moussy Apparatus and method for control of tissue/implant interactions
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
EP1130996B1 (en) 1998-11-20 2005-04-13 The University of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
EP1484338B1 (en) 1998-12-22 2007-02-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
AU773954B2 (en) * 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
ATE297190T1 (de) 1999-02-26 2005-06-15 Chiron Corp Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
MXPA01012471A (es) * 1999-06-04 2002-07-30 Alza Corp Composiciones de gel implantables y metodo de fabricacion..
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
EP2112167A3 (en) 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
AU784157B2 (en) 1999-06-25 2006-02-16 Genentech Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ES2392392T3 (es) 1999-06-28 2012-12-10 Genentech, Inc. Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
WO2001008717A1 (en) * 1999-08-03 2001-02-08 Smith & Nephew, Inc. Controlled release implantable devices
IL148114A0 (en) 1999-08-27 2002-09-12 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6705757B2 (en) * 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
EP1897944B1 (en) 1999-12-23 2011-08-10 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
PT1246917E (pt) * 2000-01-13 2009-06-02 Genentech Inc Polipéptidos stra6 humanos
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP1265630B1 (en) * 2000-03-24 2006-06-07 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
EP2348047A1 (en) 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
BR0111355A (pt) 2000-05-19 2003-04-29 Genentech Inc Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos
EP1289512B1 (en) * 2000-05-24 2005-03-09 Jordan L. Holtzman Agents and methods for increasing brain chaperonin levels
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20020068691A1 (en) * 2000-06-21 2002-06-06 Susana Salceda Method of diagnosing, monitoring, staging, imaging and treating breast cancer
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
AU7161801A (en) * 2000-06-28 2002-01-08 Amgen Inc B7-like molecules and uses thereof
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
WO2002012369A1 (en) * 2000-08-07 2002-02-14 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU9051501A (en) 2000-08-16 2002-02-25 Tyco Healthcare High consistency absorbable polymeric resin
AU8298201A (en) * 2000-08-17 2002-02-25 Tyco Healthcare Sutures and coatings made from therapeutic absorbable glass
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
JP4296341B2 (ja) * 2000-10-13 2009-07-15 独立行政法人産業技術総合研究所 リポソームの製造方法およびその装置
DK2174954T3 (en) 2000-10-18 2016-07-04 Robert Sackstein HEMATOPOIETIC CELL E-selectin / L-SELEKTINLIGAND polypeptides and methods of use thereof
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
MXPA03004578A (es) 2000-11-28 2004-05-05 Amgen Inc Nuevos polipeptidos involucrados en respuesta inmune.
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
IL156394A0 (en) * 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN1494433A (zh) 2001-01-31 2004-05-05 IDECҩ�﹫˾ Cd23拮抗剂用于治疗肿瘤性疾病的用途
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
GB0111628D0 (en) * 2001-05-11 2001-07-04 Scancell Ltd Binding member
CA2446108A1 (en) * 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
ES2371748T3 (es) 2001-05-30 2012-01-09 Genentech, Inc. Anticuerpos anti-ngf para el tratamiento de diversos trastornos.
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
EP1414517A4 (en) * 2001-06-26 2008-02-06 Photomed Technologies Inc MULTIPLE WAVELENGTH ILLUMINATOR
ES2907826T3 (es) 2001-06-26 2022-04-26 Amgen Inc Anticuerpos para OPGL
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
CN1194688C (zh) * 2001-07-03 2005-03-30 山东绿叶制药股份有限公司 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
AU2002335657A1 (en) 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
SI1427830T1 (sl) 2001-08-29 2012-08-31 Genentech Inc Bv8 nukleinske kisline in polipeptidi z mitogensko aktivnostjo
US20080085283A1 (en) * 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
ES2390531T3 (es) 2001-09-18 2012-11-13 Genentech, Inc. Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
CN100350968C (zh) * 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
IL161051A0 (en) 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
DE60231316D1 (de) 2001-10-12 2009-04-09 Schering Corp VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN
US7349733B2 (en) * 2001-11-02 2008-03-25 Ceramatel, Inc. Iontophoretic drug delivery systems
US20030119000A1 (en) * 2001-11-05 2003-06-26 Jon Polansky Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
MXPA04004664A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectables.
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
PL370914A1 (en) * 2001-11-30 2005-06-13 Pfizer Products Inc. Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
CA2471431A1 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
WO2003072738A2 (en) * 2002-02-22 2003-09-04 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
CN104805090A (zh) 2002-03-13 2015-07-29 生物基因Ma公司 抗αvβ6抗体
US7264822B2 (en) * 2002-04-03 2007-09-04 Poly-Med, Inc. Conjugated drug-polymer coated stent
AU2003243139B2 (en) * 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU2003224916B2 (en) 2002-04-10 2009-01-08 Genentech, Inc. Anti-HER2 antibody variants
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003239175A1 (en) * 2002-04-24 2003-11-10 Poly-Med, Inc. Multifaceted endovascular stent coating for preventing restenosis
AU2003235833A1 (en) 2002-04-26 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Method of screening agonistic antibody
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
WO2003103581A2 (en) 2002-06-05 2003-12-18 Genentech, Inc. Compositions and methods for liver growth and liver protection
JP2005528905A (ja) * 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
JP2006504406A (ja) 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用
EP2332956A1 (en) 2002-07-08 2011-06-15 Genentech, Inc. Antibody binding to PRO71238
NZ611387A (en) 2002-07-15 2015-05-29 Univ Texas Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
NZ537781A (en) * 2002-07-25 2008-04-30 Genentech Inc Taci antibodies and uses thereof
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2008121719A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
TWI347951B (en) 2002-09-06 2011-09-01 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
DK2332996T3 (en) 2002-09-11 2014-12-15 Genentech Inc Purification of anti-Her2 antibodies
ES2357505T3 (es) 2002-09-11 2011-04-27 Genentech, Inc. Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
CA2497661A1 (en) 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro71061
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
SI2345671T1 (sl) 2002-09-27 2016-03-31 Xencor Inc. Optimizirane Fc-variante in postopki za njihovo izdelavo
AU2003284010A1 (en) * 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
AU2003285864C1 (en) 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
EP2322202A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US20040097419A1 (en) 2002-11-19 2004-05-20 Holger Petersen Organic compounds
US20070048301A1 (en) 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EA011479B1 (ru) * 2002-12-24 2009-04-28 Ринат Ньюросайенс Корп. Антитело связывающееся с ngf, и способы его применения
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
US7060299B2 (en) * 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1585768A2 (en) * 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20050069541A1 (en) 2003-01-24 2005-03-31 Karlik Stephen J. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
JP4764334B2 (ja) 2003-02-01 2011-08-31 タノックス インコーポレーテッド 高親和性抗ヒトＩｇＥ抗体
CA2516454A1 (en) * 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
DK1616007T3 (da) 2003-04-04 2013-10-28 Univ Lausanne Inhibitorproteiner af en protease og anvendelse heraf
ATE480567T1 (de) 2003-04-04 2010-09-15 Genentech Inc Hochkonzentrierter antikörper und proteinformulierungen
UA99933C2 (ru) 2003-04-09 2012-10-25 Дженентек, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
WO2004101750A2 (en) 2003-05-09 2004-11-25 Centocor, Inc. IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2004101756A2 (en) 2003-05-09 2004-11-25 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US7375076B2 (en) * 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
EP2251355A1 (en) 2003-05-30 2010-11-17 Genentech, Inc. Treatment with anti-VEGF antibodies
AU2004251161A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
KR101148657B1 (ko) 2003-06-06 2012-07-05 제넨테크, 인크. Ｈｇｆ 베타 쇄와 ｃ-ｍｅｔ 사이의 상호작용의 변조
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
WO2005020886A2 (en) * 2003-06-27 2005-03-10 New England Biolabs, Inc. Identification and use of cofactor independent phosphoglycerate mutase as a drug target
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
US8343513B2 (en) 2003-07-18 2013-01-01 Oakwood Laboratories, Llc Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
JP5105874B2 (ja) 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
WO2005012531A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
HUE027218T2 (en) 2003-09-12 2016-10-28 Ipsen Biopharmaceuticals Inc Methods for Treatment of IGF-1 (Insulin-like Growth Factor 1) Deficiency
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
DK1680140T3 (da) * 2003-10-16 2011-06-14 Imclone Llc Fibrolast-vækstfaktorreceptor-1-inhibitorer og fremgangsmåde til behandling deraf
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
PL1682537T3 (pl) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
DK2077282T3 (en) 2003-11-05 2017-01-30 Roche Glycart Ag Antigen binding molecules with elevated Fc receptor binding affinity and effector function
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
US20050125914A1 (en) * 2003-11-18 2005-06-16 Gerard Malle Hair shaping composition comprising at least one- non-hydroxide base
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
PL1711531T3 (pl) 2003-12-10 2012-07-31 Novimmune Sa Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania
JP2008507252A (ja) 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
DK1718677T3 (da) 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
JP4503617B2 (ja) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
WO2005072159A2 (en) * 2004-01-05 2005-08-11 Biotech Studio, Llc Biotherapeutics, diagnostics and research reagents
CN101189264B (zh) 2004-01-07 2017-10-10 诺华疫苗和诊断公司 M‑csf特异性单克隆抗体及其应用
WO2005070445A2 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
EP1703895A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
EP1720564A1 (en) * 2004-02-20 2006-11-15 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2005087808A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
EP1726647B1 (en) 2004-03-19 2015-01-07 GenomIdea, Inc. Gene promoting vascular endothelial cell growth
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
SG151315A1 (en) * 2004-03-31 2009-04-30 Centocor Inc Human glp-1 mimetibodies, compositions, methods and uses
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
WO2005099756A2 (en) 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
EP1735000A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Method for augmenting b cell depletion
JP4890442B2 (ja) 2004-04-20 2012-03-07 ガラパゴス・ナムローゼ・フェンノートシャップ アミロイドベータタンパク質産生を阻害するための方法、組成物及び化合物アッセイ
EP2214018B1 (en) 2004-04-27 2013-06-26 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1773881A4 (en) * 2004-05-13 2008-08-06 Imclone Systems Inc Inhibition of macrophage-stimulating protein receptor (RON)
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
ZA200610158B (en) 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
US20050271727A1 (en) * 2004-06-07 2005-12-08 Callisyn Pharmaceuticals, Inc. Biodegradable and biocompatible crosslinked polymer hydrogel prepared from PVA and/or PEG macromer mixtures
EP2270160A1 (en) 2004-06-14 2011-01-05 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
EP2360474B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
WO2006009575A1 (en) 2004-06-22 2006-01-26 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
AU2005277831B2 (en) 2004-07-10 2012-11-22 The Institute For Cancer Research Genetically modified human natural killer cell lines
CN101014619B (zh) 2004-07-15 2010-11-03 赞科股份有限公司 优化的Fc变体
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
WO2006014729A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
JP4840939B2 (ja) 2004-08-04 2011-12-21 アムジェン インコーポレイテッド Ｄｋｋ−１に対する抗体
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
SI2990422T1 (sl) 2004-09-03 2018-10-30 Genentech, Inc. Humanizirani antagonisti proti beta7 in njihove uporabe
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP2008515813A (ja) 2004-10-06 2008-05-15 アグリ−バイオテック ピーティーワイ リミテッド 抗体産生方法
US8034345B2 (en) 2004-10-15 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-PCI antibody for regulating liver regeneration/repair
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2006047325A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
US8440627B2 (en) 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
EP1817055B1 (en) 2004-11-10 2012-12-26 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
AU2005314252B2 (en) 2004-12-06 2012-09-27 Siga Technologies, Inc. Compounds and methods for treating hemorrhagic fever viruses
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
US7973140B2 (en) 2004-12-21 2011-07-05 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
US7736872B2 (en) * 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
NZ555206A (en) 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
MX2007007587A (es) * 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
AU2005319125A1 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP2230517A1 (en) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110 antibody compositions and methods of use
WO2006076651A2 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
NZ556095A (en) 2005-01-21 2010-01-29 Genentech Inc Fixed dosing of her antibodies
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP3660049A1 (en) 2005-02-07 2020-06-03 Roche Glycart AG Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
WO2006105325A2 (en) * 2005-03-31 2006-10-05 The University Of Chicago Compositions comprising wnt-3 peptide for modulating medial-lateral neuronal topographic maps
EP1876236B9 (en) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
WO2006109045A2 (en) 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
WO2006112737A1 (en) * 2005-04-20 2006-10-26 Protemix Discovery Limited Vesiculins
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
US20080009546A1 (en) 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
JP2008539753A (ja) * 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子
WO2006124627A2 (en) * 2005-05-12 2006-11-23 Biogen Idec Ma Inc. Methods of treating conditions involving neuronal degeneration
WO2006124699A2 (en) * 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
CN102617557A (zh) 2005-05-17 2012-08-01 萨可德生物科学公司 治疗眼病的组合物和方法
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP1900814A4 (en) 2005-06-10 2010-07-21 Chugai Pharmaceutical Co Ltd SCREED SC (FV) 2-MUTANTE
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
EP2314623B1 (en) 2005-06-21 2012-07-04 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
AU2006270221B2 (en) 2005-07-15 2012-01-19 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
AU2006270009A1 (en) 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
EP1913028B1 (en) * 2005-07-28 2015-03-04 Novartis AG Use of antibody to m-csf
ES2679994T3 (es) 2005-08-11 2018-09-03 Arpi Matossian-Rogers Péptidos relacionados con TCR-V-BETA para el tratamiento y diagnóstico de enfermedad autoinmune
EP1922410A2 (en) 2005-08-15 2008-05-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CN101273140B (zh) * 2005-08-18 2013-01-16 Ambrx公司 tRNA组合物和其用途
WO2007031875A2 (en) 2005-08-26 2007-03-22 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
EP1940438A4 (en) 2005-09-08 2009-10-21 Tufts College STABILIZED GLP-1 ANALOGUES
CA2623507C (en) * 2005-09-19 2013-03-12 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CA2625447C (en) 2005-09-29 2015-06-09 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compositions and methods for stimulating gastrointestinal motility
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
EP1961065A4 (en) 2005-10-31 2009-11-11 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
EP1957099B1 (en) 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
PT1954710E (pt) * 2005-11-08 2011-06-07 Ambrx Inc Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US20090156611A1 (en) * 2005-11-11 2009-06-18 Licentia Ltd. Mammalian hedgehog signaling modulators
US8007794B2 (en) 2005-11-14 2011-08-30 Rinat Neuroscience Corporation Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
SI2090575T1 (sl) 2005-11-15 2011-08-31 Array Biopharma Inc Postopki in intermediati za pripravo N4-fenil-kinazolin-4-aminskih derivatov
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP2009520949A (ja) 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
PL1948798T3 (pl) 2005-11-18 2015-12-31 Glenmark Pharmaceuticals Sa Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1952150B1 (en) * 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
JPWO2007061029A1 (ja) 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
GB2448255A (en) 2005-12-01 2008-10-08 Trinity College Dublin Compositions and methods relating to treatment of cancer and infectious diseases
EP3006466B1 (en) 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US8466263B2 (en) * 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007066313A2 (en) 2005-12-05 2007-06-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for modulating an immune response
US8158588B2 (en) * 2005-12-05 2012-04-17 Simon Delagrave Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
EP1979001B1 (en) 2005-12-13 2012-04-11 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
CA2631491C (en) * 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0619853A2 (pt) 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
KR101538521B1 (ko) 2005-12-15 2015-07-22 제넨테크, 인크. 폴리유비퀴틴 표적화를 위한 방법 및 조성물
CN101336109A (zh) 2005-12-20 2008-12-31 赛诺科学股份公司 用于治疗和诊断下肢不宁综合征的方法与组合物
PT2359809T (pt) * 2005-12-22 2019-11-04 Novartis Ag Formulação de libertação sustentada que compreende octreótido e dois ou mais polímeros poliláctido-co-glicólido
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
ES2807928T3 (es) 2005-12-29 2021-02-24 Janssen Biotech Inc Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
EP3363455A1 (en) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
EP1984024A2 (en) 2006-01-05 2008-10-29 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CA2638785C (en) 2006-01-05 2017-02-21 Genentech, Inc. Anti-ephb4 antibodies and methods using same
JPWO2007083644A1 (ja) 2006-01-17 2009-06-11 ディナベック株式会社 新規タンパク質発現系
CA2635011A1 (en) 2006-01-26 2007-11-22 Recopharma Ab Use of sialylated fusion polypeptides for inhibition of oculotropic viruses
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
CA2637826A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
US20090221072A1 (en) * 2006-02-15 2009-09-03 Chen Thomas T Compositions and methods for modulating cell differentiation
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
RS54156B1 (sr) 2006-03-21 2015-12-31 Genentech Inc. Kombinovana terapija koja uključuje alfa5beta1 antagoniste
HRP20150347T1 (hr) 2006-03-24 2015-06-05 Array Biopharma, Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2007115148A2 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human mimetic epo hinge core mimetibodies
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP5796267B2 (ja) * 2006-04-10 2015-10-21 フージョン アンティボディーズ リミテッド 治療法
GB0620255D0 (en) * 2006-10-12 2006-11-22 Fusion Antibodies Ltd Antibody and uses thereof
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
AU2007243457B2 (en) 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
EP2246354A1 (en) 2006-04-26 2010-11-03 F. Hoffmann-La Roche AG Thieno[3,2-d]pyrimidine derivative useful as PI3K inhibitor
US8592149B2 (en) 2006-04-27 2013-11-26 Pikamab, Inc. Methods and compositions for antibody therapy
US20070259820A1 (en) * 2006-05-03 2007-11-08 The Regents Of The University Of Michigan Methods and reagents for activating heat shock protein 70
DK2548579T3 (en) 2006-05-17 2015-11-30 Ludwig Inst Cancer Res TARGET OBJECTIVE OF VEGF-B REGULATION OF FATTY ACID TRANSPORTERS FOR MODULATING HUMAN DISEASES
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
SG10201501103RA (en) 2006-05-30 2015-04-29 Genentech Inc Antibodies And Immunoconjugates And Uses Therefor
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2007143004A2 (en) 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating shiga toxin associated conditions
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2008036135A2 (en) 2006-06-01 2008-03-27 Genentech, Inc. Crystal structure of crig and c3b: crig complex
US8124743B2 (en) * 2006-06-01 2012-02-28 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US7927590B2 (en) 2006-07-10 2011-04-19 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
US7981866B2 (en) 2006-07-11 2011-07-19 University Of Medicine And Dentistry Of New Jersey MG53 compositions and methods of use
PE20081004A1 (es) 2006-07-13 2008-09-18 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
EP2046435A4 (en) * 2006-07-13 2012-06-27 Medtronic Inc METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES
MX2009000696A (es) 2006-07-19 2009-01-30 Univ Pennsylvania Wsx-1/p28 como un objetivo para respuestas anti-inflamatorias.
WO2008011513A2 (en) 2006-07-19 2008-01-24 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
WO2008011571A1 (en) * 2006-07-21 2008-01-24 Amgen Inc. Polypeptides with reduced susceptibility to oxidation and methods of making
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
CA2658786A1 (en) 2006-07-28 2008-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
KR20140033236A (ko) 2006-08-04 2014-03-17 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
WO2008023077A2 (en) * 2006-08-25 2008-02-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods for modulating an immune response
DK2292663T3 (da) 2006-08-28 2013-11-04 Kyowa Hakko Kirin Co Ltd Antagonistiske human-let-specifikke, humane monoklonale antistoffer
US10568860B2 (en) * 2006-08-30 2020-02-25 Kowa Co., Ltd. Pharmaceutical composition containing statin-encapsulated nanoparticle
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
KR101501660B1 (ko) 2006-09-01 2015-03-11 지모제넥틱스, 인코포레이티드 Ｉｌ―31 단클론 항체의 가변 영역 서열 및 사용 방법
US8420792B2 (en) * 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
CA2662753C (en) * 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
ES2530438T3 (es) 2006-09-12 2015-03-02 Genentech Inc Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
EP1905841A1 (en) * 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
EP2468293B1 (en) 2006-09-28 2014-10-22 Merck Sharp & Dohme Corp. Use of pegylated il-10 to prevent metastasis of a cancer or tumor to the lung
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2008060776A2 (en) 2006-10-03 2008-05-22 University Of Medicine And Dentistry Of New Jersey Atap peptides, nucleic acids encoding the same and associated methods of use
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
KR20090078349A (ko) * 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
ES2526292T3 (es) * 2006-10-16 2015-01-09 The Salk Institute For Biological Studies Antagonistas de la somatostatina selectivos para receptor (SSTR2)
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8067375B2 (en) * 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
DK2061814T3 (da) 2006-10-27 2012-08-27 Genentech Inc Antistoffer og immunokonjugater og anvendelse deraf.
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
MX2009004532A (es) 2006-10-27 2009-09-04 Lpath Inc Composiciones y metodos para unir esfingosina-1-fosfato.
TW201843170A (zh) 2006-11-02 2018-12-16 美商建南德克公司 人類化之抗-因子d抗體及其用途
EP2503341A3 (en) 2006-11-14 2012-10-03 Genentech, Inc. Modulators of Neuronal Regeneration
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
AU2007329352B2 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EA019661B1 (ru) 2006-12-08 2014-05-30 Лексикон Фармасьютикалз, Инк. Моноклональные антитела против angptl3
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
AR064381A1 (es) 2006-12-18 2009-04-01 Takeda Pharmaceutical Composicion de liberacion sostenida y metodos para producirla
EP2101807B1 (en) 2006-12-19 2016-05-25 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
MX2009006709A (es) 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
WO2008078179A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
UY30820A1 (es) * 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
CL2008000188A1 (es) 2007-01-23 2008-07-18 Chugai Pharmaceutical Co Ltd Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
US20080177219A1 (en) * 2007-01-23 2008-07-24 Joshi Ashok V Method for Iontophoretic Fluid Delivery
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
MX2009008104A (es) 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
PE20081760A1 (es) 2007-02-09 2009-01-01 Genentech Inc Anticuerpos anti-robo4 y sus usos
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
EP2140021B1 (en) 2007-02-22 2012-01-11 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2136831B1 (en) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
KR101208381B1 (ko) 2007-04-23 2012-12-05 인타르시아 세라퓨틱스 인코포레이티드 인슐린자극 펩티드의 현탁 제형 및 이의 용도
US20130195881A1 (en) 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
US8114630B2 (en) * 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20110065673A1 (en) 2007-05-11 2011-03-17 Bizen Chemical Co., Ltd. Novel leukotriene receptor agonist
NZ555163A (en) 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
EP1995227A1 (en) 2007-05-24 2008-11-26 Chevron USA, Inc. Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
EP1994927A1 (en) 2007-05-24 2008-11-26 Chevron USA, Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
AU2008260135A1 (en) * 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
HRP20140405T1 (hr) 2007-06-20 2014-06-20 Galapagos N.V. Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
WO2008157791A2 (en) * 2007-06-21 2008-12-24 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
AU2008268461B2 (en) 2007-06-22 2015-04-09 Children's Medical Center Corporation Methods and uses thereof of prosaposin
AU2008269689A1 (en) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
PL2185198T3 (pl) 2007-08-02 2015-06-30 Gilead Biologics Inc Inhibitory LOX i L0XL2 oraz ich zastosowania
US8153112B2 (en) * 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JP2010536366A (ja) 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 肺癌の治療及び診断の標的遺伝子のためのｅｂｉ３、ｄｌｘ５、ｎｐｔｘ１、及びｃｄｋｎ３
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
DK2195023T3 (en) 2007-08-29 2018-06-18 Sanofi Sa HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES THEREOF AND THEIR USE
EP2197918B1 (en) 2007-09-05 2013-12-18 F. Hoffmann-La Roche AG Combination therapy with type i and type ii anti-cd20 antibodies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP5963341B2 (ja) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
US20100204146A1 (en) * 2007-09-17 2010-08-12 Preglem S.A. Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US7893059B2 (en) 2007-09-24 2011-02-22 Genentech, Inc. Thiazolopyrimidine PI3K inhibitor compounds and methods of use
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
JP5685442B2 (ja) 2007-09-26 2015-03-18 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ ヘパリン結合上皮成長因子様成長因子抗原結合タンパク質
CA2701155C (en) 2007-10-02 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
CA2703705A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
DK2514436T3 (en) 2007-11-07 2018-03-12 Genentech Inc IL-22 FOR USE IN TREATMENT OF MICROBIAL DISEASES
CA2704973A1 (en) 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor b antibodies and their uses
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
JP2011502520A (ja) * 2007-11-09 2011-01-27 アナフォア インコーポレイテッド 疾患治療のためのマンノース結合レクチンの融合タンパク質
US8057796B2 (en) * 2007-11-12 2011-11-15 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
EP3257865A1 (en) 2007-11-16 2017-12-20 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
KR20100087330A (ko) 2007-11-19 2010-08-04 제넨테크, 인크. 종양 진행을 억제하기 위한 조성물 및 방법
WO2009067242A2 (en) * 2007-11-20 2009-05-28 Imclone Llc Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
DK2217265T3 (en) * 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
UY31478A1 (es) * 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
GB0723797D0 (en) 2007-12-05 2008-01-16 Immunosolv Ltd Method
TW201634479A (zh) 2007-12-05 2016-10-01 Chugai Pharmaceutical Co Ltd 抗ｎｒ１０抗體及其應用
CN101939025B (zh) 2007-12-05 2015-03-25 中外制药株式会社 搔痒症治疗药
NZ586611A (en) 2007-12-06 2012-09-28 Dana Farber Cancer Inst Inc Antibodies against influenza virus and methods of use thereof
NO2796466T3 (Direct) 2007-12-07 2018-04-21
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
EP2234628B1 (en) * 2007-12-14 2017-10-18 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
EP2851373A1 (en) 2007-12-20 2015-03-25 Xoma (Us) Llc Methods for the treatment of gout
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
PT2808343T (pt) 2007-12-26 2019-09-04 Xencor Inc Variantes fc com ligação alterada a fcrn
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AR070168A1 (es) 2008-01-31 2010-03-17 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CN102015766B (zh) 2008-03-10 2014-07-16 特罗科隆科学有限公司 用于对巨细胞病毒感染进行治疗以及诊断的组合物以及方法
KR101280716B1 (ko) 2008-03-25 2013-07-01 로슈 글리카트 아게 비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (ａｄｃｃ) 을 갖는 유형 ⅱ 항-ｃｄ20 항체의 용도
SI2279412T1 (sl) 2008-04-09 2017-10-30 Genentech, Inc., Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
CN102014957B (zh) 2008-04-21 2014-12-10 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009134917A2 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
PE20091923A1 (es) 2008-05-06 2009-12-19 Genentech Inc VARIANTES DE CRIg MADURAS POR AFINIDAD
WO2009136298A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
TR201904041T4 (tr) 2008-06-09 2019-04-22 Max Planck Gesellschaft Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
KR20110031475A (ko) 2008-06-20 2011-03-28 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
EP2138508A1 (en) 2008-06-26 2009-12-30 Helmholtz-Zentrum für Infektionsforschung GmbH Met agonists
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2899211A1 (en) 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
PL2299953T3 (pl) 2008-07-14 2017-10-31 Polypid Ltd Kompozycja nośnika leku o przedłużonym uwalnianiu
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
BRPI0910810A2 (pt) 2008-07-15 2019-09-24 Genentech Inc conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo"
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
BRPI0823049A2 (pt) 2008-09-07 2015-06-16 Glyconex Inc Anticorpos para glicoesfingolipídeos tipo 1 anti-estendidos, derivados dos mesmos e uso.
US20100129375A1 (en) 2008-09-10 2010-05-27 Genentech, Inc. Methods for inhibiting ocular angiogenesis
WO2010029118A1 (en) 2008-09-11 2010-03-18 Biofocus Dpi B.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
PL2337846T3 (pl) * 2008-09-26 2018-06-29 Ambrx, Inc. Mikroorganizmy i szczepionki z replikacją zależną od nie-naturalnych aminokwasów
ES2631915T3 (es) 2008-09-26 2017-09-06 Ambrx, Inc. Polipéptidos modificados de eritropoyetina animal y sus usos
US7982013B2 (en) 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
CA2739663A1 (en) 2008-10-10 2010-05-15 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
AR073829A1 (es) 2008-10-14 2010-12-01 Genentech Inc Variantes de inmunoglobulinas y sus usos.
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP5823867B2 (ja) 2008-10-29 2015-11-25 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の製剤
PT2356269T (pt) 2008-10-31 2016-09-13 Janssen Biotech Inc Composições, métodos e usos de scaffolds baseados em domínios de fibronectina tipo iii
NZ592436A (en) * 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
ES2453066T3 (es) 2008-11-07 2014-04-03 Sequenta, Inc. Métodos para supervisar las condiciones por análisis de secuencia
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
CA2744120A1 (en) 2008-11-17 2010-05-20 The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, A vaccinia virus protein a46 peptide and use thereof
KR101807319B1 (ko) 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
AU2009320364B2 (en) 2008-11-26 2013-05-16 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
WO2010065572A1 (en) 2008-12-04 2010-06-10 The Salk Institute For Biological Studies Sstr1-selective analogs
PT2376116E (pt) 2008-12-12 2016-02-24 Boehringer Ingelheim Int Anticorpos anti-igf
CA2747248A1 (en) 2008-12-17 2010-07-15 Sharookh Kapadia Hepatitis c virus combination therapy
JP5888980B2 (ja) 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
EP2382235B1 (en) 2008-12-19 2016-02-24 Christiane Hilger Novel caviidae allergen and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2367564A1 (en) 2008-12-22 2011-09-28 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
BRPI0918204A2 (pt) 2008-12-23 2015-12-08 Genentech Inc igv variante composição farmaceutica e kit
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
EP3059337B1 (en) 2009-01-15 2019-05-01 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
EP2390261A4 (en) 2009-01-20 2012-11-14 Hanall Biopharma Co Ltd MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
EP2391378A1 (en) 2009-01-30 2011-12-07 Université de Lausanne Use of a fragment of rasgap peptide in the treatment or prevention of metastasis
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
EA020118B1 (ru) 2009-02-13 2014-08-29 Новартис Аг Молекула нуклеиновой кислоты биосинтетического кластера, кодирующая нерибосомальные пептидсинтазы, и ее применение
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
EP2398480A1 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398479A2 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
JP2012517821A (ja) 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
EP2398494A4 (en) * 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and their methods of use
AU2010218152B2 (en) 2009-02-27 2015-04-09 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of Dengue virus infections
ES2534832T3 (es) 2009-03-10 2015-04-29 Med Discovery Sa Uso de inhibidores de serina proteasa en el tratamiento de la neutropenia
KR101781654B1 (ko) 2009-03-12 2017-09-25 제넨테크, 인크. 조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
EP3088420A1 (en) 2009-03-20 2016-11-02 F. Hoffmann-La Roche AG Bispecific anti-her antibodies
EP2679600A1 (en) * 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
UA108199C2 (uk) 2009-03-25 2015-04-10 АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
CN102325549A (zh) 2009-03-31 2012-01-18 罗氏格黎卡特股份公司 用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症
WO2010115825A2 (en) 2009-03-31 2010-10-14 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
SG174891A1 (en) 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
JP2012522977A (ja) 2009-04-01 2012-09-27 ガラパゴス・ナムローゼ・フェンノートシャップ 変形性関節症の治療のための方法及び手段
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
US9724337B2 (en) * 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
US8609101B2 (en) * 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
EA021425B1 (ru) 2009-05-05 2015-06-30 Амген Инк. Мутанты fgf21 и их применение
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
IN2012DN00352A (Direct) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CA2764835A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
KR20120044941A (ko) 2009-06-25 2012-05-08 프레드 헛친슨 켄서 리서치 센터 적응 면역의 측정방법
US8487083B2 (en) 2009-06-30 2013-07-16 OOO “Oncomax” Monoclonal antibodies capable of simultaneously binding domains II and IIIc of type 1 fibroblast growth factor receptor
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
ES2543095T3 (es) 2009-07-10 2015-08-14 Innate Pharma Agentes de unión a TLR3
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
US20110076271A1 (en) 2009-07-13 2011-03-31 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
US8992979B2 (en) 2009-07-14 2015-03-31 Polypid Ltd. Sustained-release drug carrier composition
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
BR112012003077A2 (pt) 2009-08-14 2019-09-24 Genentech Inc mercadorias biologicas para monitorar resposta em paciente para antagonistas de vegf
CN102470172B (zh) 2009-08-14 2014-09-24 罗切格利卡特公司 无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法
SG194395A1 (en) 2009-08-15 2013-11-29 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
MX357779B (es) 2009-08-28 2018-07-24 Cleveland Clinic Found Suministro de sdf-1 para el tratamiento de tejido isquemico.
KR101764449B1 (ko) 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102597776A (zh) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 鉴定响应抗癌剂的可能性升高的患者的方法
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
TWI423980B (zh) 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法
BR112012006802A2 (pt) 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
US20110104151A1 (en) * 2009-10-01 2011-05-05 Heather Nettles Microparticle compositions and methods for treating age-related macular degeneration
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
EP2485729A1 (en) 2009-10-05 2012-08-15 Vivus, Inc. Treatment with cholinergic agonists
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
EP2488186B1 (en) 2009-10-16 2017-05-24 National University of Singapore Anti-neoplastic uses of artemin antagonists
CN102574907B (zh) 2009-10-19 2015-10-21 韩诺生物制药株式会社 修饰的人肿瘤坏死因子受体i多肽或其片段以及制备它们的方法
CA2771817A1 (en) 2009-10-19 2011-04-28 Genentech, Inc. Modulators of hepatocyte growth factor activator
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20120328609A1 (en) 2009-10-22 2012-12-27 Genentech, Inc. Modulation of Axon Degeneration
EP2490718B1 (en) 2009-10-22 2016-01-13 F.Hoffmann-La Roche Ag Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CA2778481A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
LT3202898T (lt) 2009-11-02 2019-01-25 University Of Washington Terapinės nukleazės kompozicijos ir būdai
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
ES2636971T3 (es) 2009-11-05 2017-10-10 F. Hoffmann-La Roche Ag Procedimientos y composición para la secreción de polipéptidos heterógenos
MX2012005225A (es) 2009-11-12 2012-07-25 Hoffmann La Roche Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
CA2778686C (en) 2009-11-12 2015-07-21 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
EP2498803A4 (en) 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
MX2012005864A (es) 2009-11-20 2012-08-31 Amgen Inc Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
US8623416B2 (en) * 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US20130109721A1 (en) 2009-12-08 2013-05-02 Ironwood Pharmaceuticals, Inc. FAAH Inhibitors
CN102844319B (zh) 2009-12-09 2016-03-02 奥克兰联合服务有限公司 杀真菌的化合物和它们的使用方法
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
AU2010339794B2 (en) 2009-12-17 2016-09-22 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
AR079492A1 (es) 2009-12-23 2012-02-01 Ironwood Pharmaceuticals Inc Moduladores de crth2
HRP20160422T1 (hr) 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
GB0922553D0 (en) 2009-12-23 2010-02-10 Fusion Antibodies Ltd Prognostic marker
DK2516465T3 (en) 2009-12-23 2016-06-06 Hoffmann La Roche ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN107184954A (zh) 2010-01-04 2017-09-22 Mapi医药公司 包含格拉默或其药用盐的储药系统
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US8936804B2 (en) 2010-01-15 2015-01-20 Rutgers, The State University Of New Jersey Use of vanadium compounds to accelerate bone healing
US8795726B2 (en) 2010-01-19 2014-08-05 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US20130053438A1 (en) 2010-01-19 2013-02-28 Universitat Innsbruck Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
EP2528938A4 (en) 2010-01-27 2013-10-23 Childrens Medical Center PROANGIOGENIC FRAGMENTS OF PROMININ-1 AND USES THEREOF
CN102753575A (zh) 2010-01-28 2012-10-24 诺沃—诺迪斯克保健股份有限公司 因子vii融合多肽
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
WO2011100359A1 (en) 2010-02-09 2011-08-18 Ironwood Pharmaceuticals, Inc. Cannabinoid agonists
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
EP2533859B1 (en) 2010-02-10 2016-04-06 Nayacure Therapeutics Ltd Pharmaceutical compositions for the treatment and prevention of cancer
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011103599A2 (en) 2010-02-19 2011-08-25 The Regents Of The Universith Of California Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
WO2011103375A1 (en) 2010-02-19 2011-08-25 Siga Technologies, Inc. Inhibitors and methods of inhibiting bacterial and viral pathogens
MX2012009059A (es) 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
EP2538981B1 (en) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
BR112012021261A2 (pt) 2010-02-23 2020-01-07 Sanofi Anticorpo de integrina anti-alfa2 humanizada, uso do mesmo, ácido nucleico isolado codificando um anticorpo de integrina anti-alfa2beta1, vetor, célula hospedeira, composição, kit e anticorpo
AR080244A1 (es) 2010-02-23 2012-03-21 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer ovarico
TWI596114B (zh) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
PE20130393A1 (es) 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
JPWO2011118804A1 (ja) 2010-03-26 2013-07-04 国立大学法人徳島大学 新規抗ｃｄ９８抗体とその用途
WO2011119906A1 (en) 2010-03-26 2011-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
ES2601004T3 (es) 2010-04-07 2017-02-13 F. Hoffmann-La Roche Ag Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
KR20130058672A (ko) 2010-04-16 2013-06-04 제넨테크, 인크. ＰＩ3Ｋ/ＡＫＴ 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 ＦＯＸＯ３ａ
US20130116304A1 (en) 2010-04-19 2013-05-09 Ernst R. Werner Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CN105001330B (zh) 2010-04-23 2020-05-01 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
MX342590B (es) 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
US9062302B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
EP3181692A1 (en) 2010-05-07 2017-06-21 Centre National De La Recherche Scientifique Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
NZ604004A (en) 2010-05-07 2014-06-27 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
EP2568976B1 (en) 2010-05-10 2015-09-30 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011146574A1 (en) 2010-05-18 2011-11-24 Neumedicines, Inc. Il-12 formulations for enhancing hematopoiesis
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EP3190187A1 (en) 2010-05-21 2017-07-12 Peptimed, Inc. Reagents and methods for treating cancer
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MX336109B (es) 2010-06-03 2016-01-08 Genentech Inc Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN103038253A (zh) 2010-06-18 2013-04-10 西伯尔科学有限公司 作为用来稳定生物屏障的活性剂的肽
KR101834026B1 (ko) 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
JP5894154B2 (ja) 2010-06-24 2016-03-23 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化のためのアルキルグリコシドを含む組成物及び方法
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
BR112012033341B1 (pt) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc Estimulantes de sgc
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
PH12013500070A1 (en) 2010-07-12 2017-08-23 Covx Tech Ireland Ltd Multifunctional antibody conjugates
WO2012007493A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for ρi3κ p110 delta, and methods of use
US20130172853A1 (en) 2010-07-16 2013-07-04 Micell Technologies, Inc. Drug delivery medical device
CN108314733A (zh) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
US20120189618A1 (en) 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
WO2012010550A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JP2013538338A (ja) 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
EP2596128B1 (en) 2010-07-22 2015-04-22 President and Fellows of Harvard College Multiple input biologic classifier circuits for cells
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
EP2600886A1 (en) 2010-08-02 2013-06-12 Université de Lausanne Use of a peptide enhancing the ability of radiation therapy to kill cancer cells
JP2013540701A (ja) 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
CN103238069B (zh) 2010-08-17 2016-06-29 日内瓦大学 肺癌和结直肠癌中的bard1同工型及其应用
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
PL3556396T3 (pl) 2010-08-31 2022-09-12 Theraclone Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
KR101864908B1 (ko) 2010-09-01 2018-06-05 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
CN103189369B (zh) 2010-09-01 2016-08-24 吉利德康涅狄格有限公司 吡啶酮/吡嗪酮、其制备方法及使用方法
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20130296183A1 (en) 2010-09-17 2013-11-07 President And Fellows Of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2623592B1 (en) 2010-09-28 2019-05-15 NB Health Laboratory Co. Ltd. Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
CA2813304A1 (en) 2010-10-01 2012-04-05 Biogen Idec Ma Inc. Interferon-beta for use as monotherapy or in combination with other cancer therapies
WO2012045750A2 (en) 2010-10-04 2012-04-12 Centre National De La Recherche Scientifique (Cnrs) Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
AU2011311904B2 (en) 2010-10-06 2016-02-25 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
BR112013010136A2 (pt) 2010-10-25 2019-09-24 Univ Minnesota vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2632951B1 (en) 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
US8680045B2 (en) 2010-11-01 2014-03-25 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
KR20130086628A (ko) 2010-11-08 2013-08-02 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
CA2817319A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Triazole derivatives as sgc stimulators
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
KR20180069083A (ko) 2010-11-24 2018-06-22 렉시컨 파마슈티컬스 인코퍼레이티드 노텀 펙틴아세틸에스터라제에 대한 항체
DK2646470T3 (en) 2010-11-30 2017-05-08 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
CA2819501C (en) 2010-11-30 2020-03-31 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
WO2012075581A1 (en) 2010-12-06 2012-06-14 Ym Biosciences Inc. Antibodies selective for cells presenting erbb2 at high density
EP2651976A1 (en) 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
KR20140099556A (ko) 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
MA34836B1 (fr) 2010-12-17 2014-01-02 Hoffmann La Roche Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations
AU2011349502B2 (en) 2010-12-20 2016-12-22 The Rockefeller University Modulating agonistic TNFR antibodies
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088254A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
AU2011348220B2 (en) 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
US8754037B2 (en) 2010-12-23 2014-06-17 Hanall Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2663330B1 (en) 2011-01-10 2019-03-06 NovImmune S.A. Anti-tlr4 antibodies and methods of use thereof
EP2663329A2 (en) 2011-01-12 2013-11-20 Innate Pharma Tlr3 binding agents
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012100346A1 (en) 2011-01-24 2012-08-02 Ym Biosciences Inc. Antibodies selective for cells presenting egfr at high density
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
HRP20171478T1 (hr) 2011-01-27 2017-11-17 Neuren Pharmaceuticals Limited Liječenje poremećaja autističnog spektra pomoću glicil-l-2-metilprolil-l-glutaminske kiseline
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
RU2440142C1 (ru) 2011-02-07 2012-01-20 Общество С Ограниченной Ответственностью "Онкомакс" Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
BR112013020329A2 (pt) 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
BR112013020743A2 (pt) 2011-02-14 2016-10-18 Theraclone Sciences Inc composições e métodos para a terapia e diagnóstico de influenza
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102675460B (zh) 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
US8658171B2 (en) 2011-02-28 2014-02-25 Livzon Mabpharm Inc. Humanized anti-TNFα antibodies
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
JP2014507483A (ja) 2011-03-10 2014-03-27 ジェネンテック， インコーポレイテッド 血管バリヤー機能変化を伴う疾患の治療
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
RU2013142648A (ru) 2011-03-16 2015-04-27 Ф. Хоффманн-Ля Рош Аг 6,5-гетероцикл пропаргиловые спирты и их применения
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
KR20140032383A (ko) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
US9629910B2 (en) 2011-03-22 2017-04-25 The Brigham And Women's Hospital, Inc. Use of Th9 cells and IL-9 for the treatment of melanoma
KR20130137688A (ko) 2011-03-31 2013-12-17 제넨테크, 인크. 베타7 인테그린 길항제를 투여하는 방법
CN103635192B (zh) 2011-04-01 2017-07-04 基因泰克公司 Akt抑制剂化合物和化疗剂的组合以及使用方法
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
JP2014512182A (ja) 2011-04-04 2014-05-22 ユニバーシティー オブ アイオワ リサーチ ファウンデーション ワクチンの免疫原性を改善する方法
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
EP2697257B1 (en) 2011-04-13 2016-10-19 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
AU2012249601A1 (en) 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
DK2704737T3 (en) 2011-04-29 2018-04-23 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
EP2705013B1 (en) 2011-05-04 2016-03-30 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
JP2014513981A (ja) 2011-05-10 2014-06-19 アムジエン・インコーポレーテツド ＦＧＦＲ１とβ−ＫＬＯＴＨＯの相互作用を特異的に調節する化合物の同定方法
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
BR112013028892B1 (pt) 2011-05-11 2021-06-15 Children's Medical Center Corporation Proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações
WO2012162249A1 (en) 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions
SG195252A1 (en) 2011-06-02 2013-12-30 Harvard College Methods and uses for ex vivo tissue culture systems
CA2838125A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
HK1197072A1 (en) 2011-06-06 2015-01-02 Neotope Biosciences Limited Mcam antagonists and methods of treatment
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
AU2012275841A1 (en) 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
CN103946388A (zh) 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
RU2642310C2 (ru) 2011-06-28 2018-01-24 ИНХИБРКС ЭлЭлСи Слитые серпиновые полипептиды и способы их применения
US20130090294A1 (en) 2011-06-28 2013-04-11 Alternative Innovative Technologies Llc Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
AU2012282130B2 (en) 2011-07-14 2017-06-22 Pfizer Inc. Treatment with anti-PCSK9 antibodies
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
KR20140071361A (ko) 2011-08-12 2014-06-11 에프. 호프만-라 로슈 아게 피라졸로[3,4-c]피리딘 화합물 및 사용 방법
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US9605083B2 (en) 2011-08-16 2017-03-28 Emory University JAML specific binding agents, antibodies, and uses related thereto
EP2745113B1 (en) 2011-08-16 2017-03-22 Evotec (München) GmbH Markers for susceptibility to an inhibitor of an src-family kinase
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
CA2845886A1 (en) 2011-08-23 2013-02-28 President And Fellows Of Harvard College Peptide nanoparticles and uses thereof
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
EP2750695A2 (en) 2011-08-31 2014-07-09 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
ES2707580T3 (es) 2011-09-23 2019-04-04 Oncomed Pharm Inc Agentes de unión a VEGF/DLL4 y usos de los mismos
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
CN103987707B (zh) 2011-09-27 2017-11-07 霍夫曼-拉罗奇有限公司 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法
CN110655578A (zh) 2011-09-30 2020-01-07 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP3611187A1 (en) 2011-10-10 2020-02-19 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US20140271657A1 (en) 2011-10-12 2014-09-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
CA2851284A1 (en) 2011-10-13 2013-04-18 The Regents Of The University Of California Treatment of breast cancer with companion diagnostic
US20130172265A1 (en) 2011-10-14 2013-07-04 The Board Of Trustees Of The University Of Illinois Methods and Compositions for Inhibiting Tumor Cell Proliferation
US8906860B2 (en) 2011-10-14 2014-12-09 The Board Of Trustees Of The University Of Illinois Methods and compositions inhibiting tumor cell proliferation
RU2014114849A (ru) 2011-10-14 2015-11-20 Алтернатив Инновейтив Текнолоджиз Ллц Устойчивые к деградации производные белков теплового шока-70 (бтш70) и способы их применения (варианты)
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CA2856703A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2853088C (en) 2011-10-21 2018-03-13 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
PL3091029T3 (pl) 2011-10-31 2023-04-11 F. Hoffmann-La Roche Ag Formulacje przeciwciała anty-IL13
BR112014010460A2 (pt) 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
WO2013067260A1 (en) 2011-11-03 2013-05-10 Genentech, Inc. Bicyclic piperazine compounds
CA2853970A1 (en) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Alkylated piperazine compounds as inhibitors of btk activity
WO2013065017A2 (en) 2011-11-03 2013-05-10 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Platelet rich plasma (prp) and prominin-1 derived peptide stimulate lymphangiogenesis
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015500205A (ja) 2011-11-16 2015-01-05 アムジエン・インコーポレーテツド 上皮成長因子欠失変異体ｖｉｉｉ関連障害の治療方法
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2862746A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
EP2601941A1 (en) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
TW201329104A (zh) 2011-12-08 2013-07-16 Amgen Inc 人類ｌｃａｔ抗原結合蛋白質及其治療用途
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
RU2685867C2 (ru) 2011-12-15 2019-04-23 Алтернатив Инновейтив Текнолоджиз Ллц Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
WO2013096322A1 (en) 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
EP2793921B1 (en) 2011-12-22 2019-04-24 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US20140377320A1 (en) 2011-12-22 2014-12-25 Chuv, Centre Hospitalier Universitaire Vaudois Selective Plasma Activation for Medical Implants and Wound Healing Devices
EP2794659A1 (en) 2011-12-22 2014-10-29 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2800586A1 (en) 2012-01-03 2014-11-12 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
JP6413127B2 (ja) 2012-01-09 2018-10-31 コヴェックス・テクノロジーズ・アイルランド・リミテッド 変異抗体およびそのコンジュゲーション
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2802602B1 (en) 2012-01-11 2019-03-27 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
EA027976B1 (ru) 2012-01-13 2017-09-29 Дзе Дженерал Хоспитал Корпорейшн Анестезирующие соединения и способы их применения
HK1204933A1 (zh) 2012-01-13 2015-12-11 霍夫曼-拉罗奇有限公司 用於识别适於用vegf拮抗剂治疗的患者的生物标记物
AU2013211846A1 (en) 2012-01-26 2014-08-14 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
MX353190B (es) 2012-01-30 2018-01-05 F Hoffmann La Roche Ag Star Derivados de isoquinolina y naftiridina.
SG10201700160RA (en) 2012-02-06 2017-03-30 Inhibrx Lp Cd47 antibodies and methods of use thereof
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
CA2864484C (en) 2012-02-17 2019-07-02 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
JP2015507001A (ja) 2012-02-17 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式化合物及びその使用方法
EP2819689A1 (en) 2012-03-01 2015-01-07 Yeda Research and Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
CN104244967A (zh) 2012-03-01 2014-12-24 耶达研究与发展有限公司 用于抑制和治疗非自身免疫性糖尿病的Hsp60衍生肽和肽类似物
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US9567316B2 (en) 2012-03-07 2017-02-14 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
RS58964B1 (sr) 2012-03-13 2019-08-30 Hoffmann La Roche Kombinovana terapija za lečenje karcinoma jajnika
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
EP2825191B1 (en) 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
WO2013142119A1 (en) 2012-03-20 2013-09-26 Trustees Of Tufts College Silk reservoirs for drug delivery
IN2014DN08604A (Direct) 2012-03-22 2015-05-22 Univ Michigan
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
MX2014011500A (es) 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
JP6419064B2 (ja) 2012-03-29 2018-11-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用
CN104271772A (zh) 2012-03-29 2015-01-07 科罗拉多州立大学董事会,公司实体 点击核酸
BR112014024219A8 (pt) 2012-03-30 2017-07-25 Genentech Inc Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
WO2013155346A1 (en) 2012-04-11 2013-10-17 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6199957B2 (ja) 2012-04-16 2017-09-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 免疫応答を調節するためのメソポーラスシリカ組成物
US20150118237A1 (en) 2012-04-23 2015-04-30 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
JP2015516980A (ja) 2012-04-26 2015-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とベンダムスチンとの併用
JP2015516813A (ja) 2012-04-27 2015-06-18 シトムクス セラピューティクス，インコーポレイティド 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
HK1207655A1 (en) 2012-05-04 2016-02-05 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
CN107586832B (zh) 2012-05-08 2021-03-30 适应生物技术公司 用于测量和校准多重pcr反应中的扩增偏倚的组合物和方法
JP2015517512A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体の更なる薬剤との併用
EP2849784A1 (en) 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
EP3594239B1 (en) 2012-05-21 2024-10-30 F. Hoffmann-La Roche AG Methods for improving safety of blood-brain barrier transport
KR20150023445A (ko) 2012-05-22 2015-03-05 에프. 호프만-라 로슈 아게 치환된 다이피리딜아민 및 이의 용도
WO2013177224A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174947A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
MX2014014531A (es) 2012-05-31 2015-04-08 Hoffmann La Roche Derivados de aminoquinazolina y piridopirimidina.
DK2855527T3 (en) 2012-05-31 2018-11-26 Innate Pharma TLR3 BINDERS
CA3228586A1 (en) 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
CA2871359A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2014004676A1 (en) 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
RU2665462C2 (ru) 2012-06-27 2018-08-30 Ф. Хоффманн-Ля Рош Аг Соединения 5-азаиндазола и способы их применения
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
CN110256567B (zh) 2012-06-27 2023-04-25 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
CA2877441A1 (en) 2012-07-02 2014-01-09 Medizinische Universitat Wien Complement split product c4d for the treatment of inflammatory conditions
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
AU2013295706A1 (en) 2012-07-25 2015-02-19 Sarcode Bioscience Inc. LFA-1 inhibitor and polymorph thereof
EP3698809A1 (en) 2012-07-31 2020-08-26 The Brigham & Women's Hospital, Inc. Modulation of the immune response using agents binding tim-3 and ceacam-1
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
EP3446709A1 (en) 2012-08-07 2019-02-27 F. Hoffmann-La Roche AG Combination therapy for the treatment of glioblastoma
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
US20150210758A1 (en) 2012-08-14 2015-07-30 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9119858B2 (en) 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
KR101885044B1 (ko) 2012-08-29 2018-08-02 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
BR112015002493A8 (pt) 2012-08-30 2019-07-30 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, kit e uso de um composto”
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
KR102158467B1 (ko) 2012-09-07 2020-09-25 제넨테크, 인크. Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2014043344A1 (en) 2012-09-13 2014-03-20 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
PL2900657T3 (pl) 2012-09-26 2020-07-27 F.Hoffmann-La Roche Ag Cykliczne związki eterowe pirazol-4-ilo-heterocyklilo-karboksyamidu i sposoby stosowania
MX2015003565A (es) 2012-09-27 2015-06-22 Hoffmann La Roche Compuestos de sulfanamida sustituidos.
CA2886647A1 (en) 2012-10-01 2014-04-10 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
CN114507282B (zh) 2012-10-04 2025-05-16 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
ES2738305T3 (es) 2012-10-05 2020-01-21 Hoffmann La Roche Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
US9540439B2 (en) 2012-10-08 2017-01-10 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
EP2906241B1 (en) 2012-10-12 2020-01-08 The Brigham and Women's Hospital, Inc. Enhancement of the immune response
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
BR112015008612A2 (pt) 2012-10-17 2017-09-26 Vascular Biogenics Ltd métodos de tratamento utilizando adenovirus
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
CN104768579A (zh) 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
JP6348115B2 (ja) 2012-10-26 2018-06-27 ザ ユニバーシティー オブ クイーンズランド がん療法のためのエンドサイトーシス阻害剤および抗体の使用
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
EP2918678B1 (en) 2012-11-09 2019-01-30 GeneFrontier Corporation Anti-adam28 antibody for treating cancer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3511718A1 (en) 2012-11-30 2019-07-17 F. Hoffmann-La Roche AG Pd-l1 inhibitor
CA3155275A1 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
KR20150092760A (ko) 2012-12-07 2015-08-13 더 제너럴 하스피탈 코포레이션 Pi3k/akt 저해제 화합물과 her3/egfr 저해제 화합물의 조합 및 과다증식성 장애의 치료에 있어서의 이의 용도
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013358968B2 (en) 2012-12-13 2017-12-21 Warsaw Orthopedic, Inc. Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
EP3266466A1 (en) 2012-12-20 2018-01-10 Medimmune, LLC Liquid antibody formulation with improved aggregation properties
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CN110981964B (zh) 2013-01-14 2023-09-15 Xencor股份有限公司 新型异二聚体蛋白
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP2945938B1 (en) 2013-01-18 2018-03-07 F. Hoffmann-La Roche AG 3-substituted pyrazoles and use as dlk inhibitors
EP2948433B1 (en) 2013-01-22 2017-04-26 Technische Universität Graz Atglistatin as lipase inhibitor
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US9701743B2 (en) 2014-02-20 2017-07-11 Allergan, Inc. Complement component C5 antibodies
MX369175B (es) 2013-02-25 2019-10-30 Genentech Inc Métodos para detectar mutantes de akt resistentes a fármacos.
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US11338036B2 (en) 2013-03-08 2022-05-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9717583B2 (en) 2014-03-13 2017-08-01 Cell and Molecular Tissue Engineering, LLC Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
EP2968540A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
EP2972322B1 (en) 2013-03-14 2019-03-06 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
EP2972381A2 (en) 2013-03-14 2016-01-20 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CA2907184C (en) 2013-03-15 2022-12-06 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
JP6427552B2 (ja) 2013-03-15 2018-11-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド フラビウイルス中和抗体およびその使用方法
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
HUE059178T2 (hu) 2013-03-15 2022-10-28 Cyclerion Therapeutics Inc SGC stimulátorok
US11156608B2 (en) 2013-03-15 2021-10-26 The Trustees Of The University Of Pennsylvania Method for the site-specific covalent cross-linking of antibodies to surfaces
AU2014233494B2 (en) 2013-03-15 2018-10-04 Genentech, Inc. IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
US9872899B2 (en) 2013-03-15 2018-01-23 Biological Mimetics, Inc. Immunogenic human rhinovirus (HRV) compositions
EP2970470B1 (en) 2013-03-15 2019-12-04 Amgen Inc. Human pac1 antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
HRP20191470T1 (hr) 2013-03-15 2020-01-10 Xencor, Inc. Heterodimerni proteini
KR102207859B1 (ko) 2013-03-15 2021-01-27 메모리얼 슬로안 케터링 캔서 센터 고 친화도 항-gd2 항체
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US20160046679A1 (en) 2013-03-15 2016-02-18 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
EA030611B1 (ru) 2013-03-15 2018-08-31 Кэнсер Рисерч Текнолоджи, Ллк Способы и композиции для модуляции гамма-глутамилового цикла
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
EP2968480B1 (en) 2013-03-15 2020-10-14 Amgen Inc. Treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
KR20160005333A (ko) 2013-03-15 2016-01-14 유벤타스 세라퓨틱스, 인크. 흉터 형성을 완화시키기 위한 sdf-1의 용도
EP2975936A4 (en) 2013-03-22 2017-03-15 University of Hawaii Novel stat3 inhibitors
WO2014160871A2 (en) 2013-03-27 2014-10-02 The General Hospital Corporation Methods and agents for treating alzheimer's disease
WO2014160753A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
JP6109622B2 (ja) * 2013-04-01 2017-04-05 株式会社クレハ 徐放性成形体およびその製造方法
EP2983681B1 (en) 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
AU2014250138B2 (en) 2013-04-05 2018-11-15 Manuka Health New Zealand Limited Therapeutic compositions comprising extracts of propolis and uses thereof
ITTO20130284A1 (it) * 2013-04-09 2014-10-10 Fond Istituto Italiano Di Tecnologia Procedimento per la produzione di microparticelle polimeriche sagomate
MX2015014861A (es) 2013-05-01 2016-03-09 Hoffmann La Roche Pirimidinas sustituidas con heterocicloalquilo c-enlazado y sus usos.
KR101836431B1 (ko) 2013-05-01 2018-03-09 에프. 호프만-라 로슈 아게 바이헤테로아릴 화합물 및 이의 용도
US11293064B2 (en) 2013-05-02 2022-04-05 Thomas Jefferson University Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases
KR20160005749A (ko) 2013-05-07 2016-01-15 리나트 뉴로사이언스 코프. 항-글루카곤 수용체 항체 및 이의 사용 방법
KR20180059584A (ko) 2013-05-15 2018-06-04 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
PE20151926A1 (es) 2013-05-20 2016-01-07 Genentech Inc Anticuerpos de receptores de antitransferrina y metodos de uso
US10501803B2 (en) 2013-05-21 2019-12-10 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
EP2805730A1 (en) 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
US10053510B2 (en) 2013-05-24 2018-08-21 Promis Neurosciences Inc. FasR antibodies and methods of use
WO2014193800A2 (en) 2013-05-28 2014-12-04 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
CN105555803B (zh) 2013-05-30 2019-09-10 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
AU2014273939B2 (en) 2013-05-31 2019-09-19 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
JP6506262B2 (ja) 2013-05-31 2019-04-24 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
EP2810648A1 (en) 2013-06-04 2014-12-10 Daniel Rauh Targeting domain-domain interaction for the identification of kinase modulators
CN105658240A (zh) 2013-06-04 2016-06-08 西托姆克斯治疗公司 用于缀合可活化抗体的组合物和方法
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
BR112015030972A8 (pt) 2013-06-11 2020-01-28 Janssen Biotech Inc células sc-beta e composições e métodos para geração das mesmas
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
AU2014280847B2 (en) 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
CN110698481B (zh) 2013-07-03 2023-02-28 豪夫迈·罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
AU2014286872B2 (en) 2013-07-05 2020-01-23 Formation Biologics Inc. EGFR antibody conjugates
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
BR112016001611B1 (pt) 2013-07-25 2024-01-09 Cytomx Therapeutics, Inc Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
EA037355B1 (ru) 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
JP6506280B2 (ja) 2013-08-02 2019-05-08 ファイザー・インク 抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
EP2835136A1 (en) 2013-08-07 2015-02-11 PregLem S.A. Somatostatin Receptor Modulator for the treatment of infertility
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
CA2922361C (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CA2923145C (en) 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
JP6745220B2 (ja) 2013-09-16 2020-08-26 ツェーエムエム−フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン
EP3046588B1 (en) 2013-09-17 2022-03-02 OBI Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
JP6445440B2 (ja) 2013-09-20 2018-12-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
EP3521431A1 (en) 2013-09-25 2019-08-07 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
CA3214529A1 (en) 2013-09-25 2015-04-02 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015048543A1 (en) 2013-09-26 2015-04-02 Atterocor, Inc. Treating disorders associated with aberrant adrenocortical cell behavior
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
MX384984B (es) 2013-10-10 2025-03-14 Beth Israel Deaconess Medical Ct Inc Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
CN105612153B (zh) 2013-10-11 2018-09-14 豪夫迈·罗氏有限公司 用作trpa1调节剂的取代的杂环磺酰胺化合物
US20160304622A1 (en) 2013-10-15 2016-10-20 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
US10780070B2 (en) 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight
WO2015058197A1 (en) 2013-10-18 2015-04-23 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight
US20160250285A1 (en) 2013-10-30 2016-09-01 University Of Western Australia Neuroprotective peptides
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015066557A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease molecules with altered glycosylation and methods
CN105813637A (zh) 2013-11-01 2016-07-27 卑尔根技术转移公司 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
ES2909014T3 (es) 2013-11-26 2022-05-04 Brigham & Womens Hospital Inc Composiciones y métodos para modular una respuesta inmunitaria
JP6275846B2 (ja) 2013-12-05 2018-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物
CA2932787A1 (en) 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
JP2016540017A (ja) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
US20160333063A1 (en) 2013-12-13 2016-11-17 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
US9873724B2 (en) 2013-12-20 2018-01-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pro-angiogenic peptides and peptide conjugates
CA3204788C (en) 2013-12-20 2025-11-18 Genentech, Inc. ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
BR112016017649B1 (pt) 2014-01-31 2024-01-30 Cytomx Therapeutics, Inc Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso da composição farmacêutica e quantidade terapeuticamente eficaz da dita composição no tratamento de um distúrbio ou doença
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
WO2015121457A1 (en) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
EP3450571B1 (en) 2014-02-24 2023-04-05 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
EP3110845A1 (en) 2014-02-27 2017-01-04 Allergan, Inc. Complement factor bb antibodies
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2741740T3 (es) 2014-03-05 2020-02-12 Adaptive Biotechnologies Corp Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios
US20150252434A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
WO2015134973A1 (en) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
JP6554480B2 (ja) 2014-03-18 2019-07-31 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト オキセパン−２−イル−ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
ES2750563T3 (es) 2014-03-20 2020-03-26 Bristol Myers Squibb Co Moléculas con una estructura basada en fibronectina estabilizada
BR112016021423A2 (pt) 2014-03-21 2017-11-14 Teva Pharmaceuticals Int Gmbh anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
KR102327996B1 (ko) 2014-03-28 2021-11-17 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
CA2944456C (en) 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3125866B1 (en) 2014-04-04 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
CA2983796A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
PT3137114T (pt) 2014-04-30 2021-02-26 Pfizer Conjugados anticorpo-fármaco anti-ptk7
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
HUE063273T2 (hu) 2014-05-06 2024-01-28 Hoffmann La Roche Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
US20170073690A1 (en) 2014-05-15 2017-03-16 CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH Antagonists of slc38a9 and their use in therapy
JP2017521479A (ja) 2014-05-15 2017-08-03 ラニ セラピューティクス， エルエルシー ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
US20170119851A1 (en) 2014-05-19 2017-05-04 Novartis Ag Methods of treating anorexia
EA028614B1 (ru) 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170005142A (ko) 2014-05-27 2017-01-11 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
WO2015184260A2 (en) 2014-05-30 2015-12-03 The Johns Hopkins University Methods for treating mendelian disorders of the epigenetic machinery
ES2761675T3 (es) 2014-05-30 2020-05-20 Henlix Biotech Co Ltd Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
DK3151859T3 (da) 2014-06-09 2021-02-15 Ultragenyx Pharmaceutical Inc Virkningsfuld og effektiv kontrol af serumphosphat til optimal knogledannelse
BR112016028750A2 (pt) 2014-06-11 2017-11-14 Gilead Sciences Inc ?métodos para tratar, prevenir, ou melhorar pelo menos um sintoma associado e para diagnosticar e monitorar insuficiência cardíaca ou fibrilação atrial, inibidor da lisil oxidase ativa ou proteína lisil tipo oxidase, e, composição?
AP2016009647A0 (en) 2014-06-13 2016-12-31 Santa Maria Biotherapeutics Inc Formulated receptor polypeptides and related methods
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
CN114057857A (zh) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3166974A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
JP2017523980A (ja) 2014-08-06 2017-08-24 ライナット ニューロサイエンス コーポレイション Ｌｄｌ−コレステロールを低下させるための方法
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
EP3191131A4 (en) 2014-08-21 2018-09-05 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
EA201790434A1 (ru) 2014-08-22 2017-07-31 Окленд Юнисервисиз Лимитед Модуляторы каналов
WO2016032595A1 (en) 2014-08-27 2016-03-03 Peptimed, Inc. Anti-tumor compositions and methods
US10414809B2 (en) 2014-09-01 2019-09-17 Academia Sinica Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
CA2959757A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN111303159A (zh) 2014-10-02 2020-06-19 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
CA2962976A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
EP3206707B1 (en) 2014-10-13 2020-12-02 University of Maryland, Baltimore Fc-ela-32 and its use in the treatment of cardiac conditions
CA2962451C (en) 2014-10-21 2023-01-17 Sciclone Pharmaceuticals, Inc. Treatment of cancer with immune stimulators
CN110078814B (zh) 2014-10-24 2024-03-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016077083A1 (en) 2014-11-05 2016-05-19 University Of The Sciences In Philadelphia A high molecular weight biodegradable gelatin-doxorubicin conjugate
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015350190B2 (en) 2014-11-18 2021-08-05 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016079321A1 (en) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
EP3224277B1 (en) 2014-11-25 2020-08-26 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US20180057839A1 (en) 2014-11-26 2018-03-01 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
CA2965540A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
HK1244230A1 (zh) 2014-12-03 2018-08-03 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US20170360726A1 (en) 2014-12-05 2017-12-21 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
CA2969699A1 (en) 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP2018502840A (ja) 2014-12-10 2018-02-01 ジェネンテック， インコーポレイテッド 血液脳関門受容体抗体及び使用方法
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
TW202534076A (zh) 2014-12-18 2025-09-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
AU2015371312B2 (en) 2014-12-24 2022-01-27 Genentech, Inc. Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
CA2974369A1 (en) 2015-01-20 2016-07-28 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CA2972731A1 (en) 2015-01-24 2016-07-28 Chi-Huey Wong Cancer markers and methods of use thereof
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
EP3250590B1 (en) 2015-01-30 2021-09-15 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced anti-ssea4 antibody efficacy
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
US10383945B2 (en) 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
HRP20221284T1 (hr) 2015-02-19 2022-12-23 Compugen Ltd. Anti-pvrig antitijela i postupci uporabe
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
KR20170138410A (ko) 2015-02-23 2017-12-15 시걸 테라퓨틱스 에스에이에스 비-천연 세마포린 3 및 이의 의학적 용도
EP3262035A1 (en) 2015-02-25 2018-01-03 F. Hoffmann-La Roche AG Alkynyl alcohols and methods of use
CN113209289A (zh) 2015-02-26 2021-08-06 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
MA41599A (fr) 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
RS63903B1 (sr) 2015-03-03 2023-02-28 Kymab Ltd Antitela, upotrebe i metode
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016144860A1 (en) 2015-03-06 2016-09-15 Ironwood Pharmaceuticals, Inc. Faah inhibitors for the treatment or prevention of nausea
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
JP6903587B2 (ja) 2015-04-03 2021-07-14 ユーリカ セラピューティックス， インコーポレイテッド Ａｆｐペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
US20160287565A1 (en) 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
MX2017013297A (es) 2015-04-13 2018-06-19 Pfizer Anticuerpos terapeuticos y sus usos.
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
PT3283524T (pt) 2015-04-17 2023-06-05 Amgen Res Munich Gmbh Construções de anticorpos biespecíficos para cdh3 e cd3
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
WO2016170102A1 (en) 2015-04-22 2016-10-27 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
US20180110823A1 (en) 2015-04-22 2018-04-26 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
ES2884267T3 (es) 2015-04-24 2021-12-10 Viiv Healthcare Uk No 5 Ltd Polipéptidos dirigidos a la fusión con el vih
KR20240093813A (ko) 2015-04-24 2024-06-24 제넨테크, 인크. 다중특이적 항원-결합 단백질
CN113546036A (zh) 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
HRP20200721T1 (hr) 2015-05-04 2020-10-02 Cytomx Therapeutics Inc. Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe
TWI726879B (zh) 2015-05-04 2021-05-11 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
EP3292151A1 (en) 2015-05-04 2018-03-14 Cytomx Therapeutics Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
SG11201708620QA (en) 2015-05-08 2017-11-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
CA3024195A1 (en) 2015-05-12 2016-11-17 The Trustees Of The University Of Pennsylvania Compositions and methods for making antibody conjugates
MX2017014381A (es) 2015-05-12 2018-03-02 Genentech Inc Metodos terapeuticos y diagnosticos para cancer.
EP3294072A4 (en) 2015-05-15 2019-03-13 The Johns Hopkins University NOVEL PRENATAL FOOD SUPPLEMENT WITH FLUORIDE
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
HK1248773A1 (zh) 2015-05-29 2018-10-19 豪夫迈‧罗氏有限公司 用於癌症的治疗和诊断方法
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
CA2988011C (en) 2015-06-04 2021-03-23 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
MX2017015700A (es) 2015-06-04 2018-11-09 Ospedale San Raffaele Srl Igfbp3 y sus usos.
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
UA127809C2 (uk) 2015-06-24 2024-01-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
WO2017001362A1 (en) 2015-06-29 2017-01-05 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
CN112047960B (zh) 2015-07-02 2024-08-02 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
MX2018000135A (es) 2015-07-07 2018-03-23 Genentech Inc Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
WO2017007955A1 (en) 2015-07-07 2017-01-12 The Research Foundation For The State University Of New York Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
DK3322733T3 (da) 2015-07-13 2021-10-18 Compugen Ltd Hide1-sammensætninger og fremgangsmåder
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
MX2018001075A (es) 2015-07-28 2019-04-15 Vyome Therapeutics Ltd Agentes terapeuticos y profilacticos antibacterianos.
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA034571B1 (ru) 2015-07-31 2020-02-21 Дзе Джонс Хопкинс Юниверсити Пролекарства аналогов глутамина
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
CA2994162A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Glutamine antagonists for the treatment of cognitive deficits
CA2994256A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3331902B1 (en) 2015-08-07 2021-04-28 ALX Oncology Inc. Constructs having a sirp-alpha domain or variant thereof
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
KR20180039726A (ko) 2015-09-04 2018-04-18 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인슐린 면역글로불린 융합 단백질
HK1256912A1 (zh) 2015-09-04 2019-10-04 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
CA2998174A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
HUE072064T2 (hu) 2015-09-15 2025-10-28 Scholar Rock Inc Pro/látens miosztatin elleni antitestek és alkalmazásuk
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
CN108884147B (zh) 2015-09-23 2024-02-27 百时美施贵宝公司 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
MX2018004041A (es) 2015-10-01 2018-11-09 Amgen Inc Tratamiento de trastornos de acidos biliares.
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CR20180149A (es) 2015-10-02 2018-04-05 Hoffmann La Roche Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
PT3359572T (pt) 2015-10-06 2025-01-27 H Hoffnabb La Roche Ag Método para o tratamento da esclerose múltipla
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2023034901A1 (en) 2021-09-01 2023-03-09 The Broad Institute, Inc. Tumor avatar vaccine compositions and uses thereof
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
ES2846848T3 (es) 2015-10-26 2021-07-29 Harvard College Polisacáridos reducidos y oxidados y métodos de uso de los mismos
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
LT3368578T (lt) 2015-10-30 2021-05-25 F. Hoffmann-La Roche Ag Antikūnai prieš htra1 ir jų naudojimo būdai
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CA3004048A1 (en) 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
SG11201803211TA (en) 2015-11-03 2018-05-30 Ambrx Inc Anti-cd3-folate conjugates and their uses
CN108834415B (zh) 2015-11-13 2021-12-24 多曼治疗学公司 作为ii组代谢型谷氨酸受体的别构调节剂的取代的三环1,4-苯并二氮杂䓬酮衍生物
EP3377107B1 (en) 2015-11-19 2020-08-12 H. Hoffnabb-La Roche Ag Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
TWI703160B (zh) 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
CN109069871A (zh) 2015-12-04 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的新抗体
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
SMT202100709T1 (it) 2015-12-09 2022-01-10 Univ Wien Med Composti di platino funzionalizzati con monomaleimmide per la terapia del cancro
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
MA43567A (fr) 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
JP6783870B2 (ja) 2015-12-18 2020-11-11 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 心血管病を予防及び治療するための新しい方法
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
CA3009814A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
WO2017121855A1 (en) 2016-01-15 2017-07-20 Universität Hamburg Flavonoide-type compounds bearing an o-rhamnosyl residue
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CN109219617A (zh) 2016-02-03 2019-01-15 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
TWI767899B (zh) 2016-02-03 2022-06-21 德商安美基研究（慕尼黑）公司 Psma及cd3雙特異性t細胞嚙合抗體構築體
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
US10098909B2 (en) 2016-02-05 2018-10-16 University Of South Florida Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
EP4299072A3 (en) 2016-02-10 2024-05-01 Rutgers, the State University of New Jersey Novel anti-lam antibodies
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
JP2019508496A (ja) 2016-02-15 2019-03-28 チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療法のためのｔａｆ１阻害剤
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
JP2019517991A (ja) 2016-03-01 2019-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 低減したａｄｃｐを有するオビヌツズマブ及びリツキシマブ変異体
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
SG11201807176XA (en) 2016-03-11 2018-09-27 Scholar Rock Inc TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
EP3429693B1 (en) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
HK1256040A1 (zh) 2016-03-28 2019-09-13 心悦生医股份有限公司 含有鞣酸的组合物及其用途
JP2019513144A (ja) 2016-03-29 2019-05-23 オービーアイ ファーマ，インコーポレイテッド 抗体、医薬組成物及び方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
JP2019513752A (ja) 2016-04-07 2019-05-30 ケース ウエスタン リザーブ ユニバーシティ 神経変性疾患を治療するためのｔｄｐ−４３のミトコンドリア局在化阻害剤
US20190111069A1 (en) 2016-04-15 2019-04-18 Oxford University Innovation Limited Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
MX2018012493A (es) 2016-04-15 2019-06-06 Genentech Inc Métodos para controlar y tratar el cáncer.
JP7503887B2 (ja) 2016-04-15 2024-06-21 ジェネンテック， インコーポレイテッド がんを監視及び治療するための方法
JP7544465B2 (ja) 2016-04-22 2024-09-03 オービーアイ ファーマ，インコーポレイテッド グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
NZ775714A (en) 2016-05-04 2024-12-20 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
CN114703244A (zh) 2016-05-10 2022-07-05 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法
WO2017200987A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
HUE064454T2 (hu) 2016-06-08 2024-03-28 Xencor Inc IgG4-gyel kapcsolatos betegségek kezelése CD32B-vel keresztkötõ, CD-19 elleni ellenanyagokkal
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer
WO2017222834A1 (en) 2016-06-10 2017-12-28 City Of Hope Compositions and methods for mitochondrial genome editing
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN109843882A (zh) 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2017216279A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
WO2018005954A2 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
EP3484448B1 (en) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CA3030783A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
MX2019000643A (es) 2016-07-15 2019-06-13 Poseida Therapeutics Inc Receptores de antigenos quimericos y metodos de uso.
CA3030834A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
CN109476640B (zh) 2016-07-20 2022-02-25 豪夫迈·罗氏有限公司 双环脯氨酸化合物
CN109476628B (zh) 2016-07-20 2022-01-11 豪夫迈·罗氏有限公司 作为trpa1调节剂的磺酰基环烷基酰胺化合物
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3487858A4 (en) 2016-07-21 2020-01-01 The University of North Carolina at Chapel Hill INHIBITORS OF MICROBIAL BETA GLUCURONIDASE ENZYMES AND USES THEREOF
WO2018015466A1 (en) 2016-07-22 2018-01-25 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal metallic nanoparticles and uses thereof
AU2017300788B2 (en) 2016-07-22 2023-11-16 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
US20190275073A1 (en) 2016-07-22 2019-09-12 Ecole polytechnique fédérale de Lausanne (EPFL) Virucidal compounds and uses thereof
EP3490592A4 (en) 2016-07-27 2020-03-25 OBI Pharma, Inc. IMMUNOGENIC / THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
WO2018023121A1 (en) 2016-07-29 2018-02-01 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
US20200030295A1 (en) 2016-08-02 2020-01-30 Friedrich-Alexander-Universität Erlangen-Nürnberg Heterocyclic diamidines
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
US20190185556A1 (en) 2016-08-08 2019-06-20 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
EP3497093B1 (en) 2016-08-12 2021-09-15 F. Hoffmann-La Roche AG Sulfonyl pyridyl trp inhibitors
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
MX2019002121A (es) 2016-08-23 2019-08-12 Genentech Inc Tratamiento conjunto para tratar el cancer de pancreas.
WO2018037059A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
WO2018037058A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
SMT202300251T1 (it) 2016-08-31 2023-09-06 Mapi Pharma Ltd Sistemi a deposito comprendenti glatiramer acetato
KR102854313B1 (ko) 2016-09-02 2025-09-04 티센토 쎄라퓨틱스 인크. 융합된 비시클릭 sGC 자극제
IL265144B2 (en) 2016-09-06 2024-10-01 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
EP3512564B1 (en) 2016-09-14 2024-01-17 The Trustees of The University of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
CN109923126B (zh) 2016-09-16 2022-06-03 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
ES2875329T3 (es) 2016-09-16 2021-11-10 Res Triangle Inst Antagonistas de opioides kappa de tetrahidroisoquinolina
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
CA3037661A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
IL265759B2 (en) 2016-10-06 2025-10-01 Genentech Inc Therapeutic and diagnostic methods for cancer
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
RU2019114175A (ru) 2016-10-14 2020-11-16 Ксенкор, Инк. Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1
CN109843886B (zh) 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CA3040343A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018078031A1 (en) 2016-10-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of derivation and/or propagation of epithelial cells
US11117968B2 (en) 2016-11-03 2021-09-14 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3535299A1 (en) 2016-11-04 2019-09-11 Novimmune S.A. Anti-cd19 antibodies and methods of use thereof
SG10202104865UA (en) 2016-11-08 2021-06-29 Cyclerion Therapeutics Inc Treatment of cns diseases with sgc stimulators
CN110267949A (zh) 2016-11-08 2019-09-20 塞科里昂医疗股份有限公司 sGC刺激剂
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
WO2018087276A1 (en) 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 modulators and uses thereof
MX2019005443A (es) 2016-11-14 2019-11-21 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
CN109982720A (zh) 2016-11-22 2019-07-05 豪夫迈·罗氏有限公司 抗体药物缀合物
CN110225911B (zh) 2016-11-28 2022-04-05 豪夫迈·罗氏有限公司 噁二唑酮瞬时受体电位通道抑制剂
MA46937A (fr) 2016-11-30 2019-10-09 Oncotyrol Center For Personalized Cancer Medicine Gmbh 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
EP4190318A1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CA3045475A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
BR112019012071A2 (pt) 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
JP7158740B2 (ja) 2016-12-15 2022-10-24 タレンゲン インターナショナル リミテッド 冠状動脈アテローム性硬化症およびその合併症を治療するための方法
WO2018107704A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种抑制胰岛β细胞凋亡的方法
US20190328848A1 (en) 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating drug-induced renal injury
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107697A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肺纤维化的方法
US20190365871A1 (en) 2016-12-15 2019-12-05 Talengen International Limited Drug for preventing and treating osteoporosis and uses thereof
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
PL3557998T3 (pl) 2016-12-23 2024-03-11 Aquinnah Pharmaceuticals Inc. Związki, kompozycje i sposoby ich stosowania
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
EA039807B1 (ru) 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
EP3565592B1 (en) 2017-01-06 2023-03-01 Scholar Rock, Inc. Treating metabolic diseases by inhibiting myostatin activation
CA3049005A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Isoform-specific, context-permissive tgf.beta.1 inhibitors and use thereof
US11529391B2 (en) 2017-01-09 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
EP3565833A1 (en) 2017-01-09 2019-11-13 Torch Therapeutics Conditionally effective bispecific therapeutics
EP3568143B1 (en) 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
WO2018136935A1 (en) 2017-01-23 2018-07-26 University Of Hawaii 2-arylsulfonamido-n-arylacetamide derivatized stat3 inhibitors
JP7246321B2 (ja) 2017-01-24 2023-03-27 インネイト ファーマ ＮＫｐ４６結合物質
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
JP2020506947A (ja) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
CN110461871B (zh) 2017-02-16 2024-04-26 索纳特生物疗法公司 白蛋白结合结构域融合蛋白
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
RU2019127550A (ru) 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. Анти-gitr антитела и способы их использования
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
JP7178357B2 (ja) 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CA3055574A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
US10421968B2 (en) 2017-03-15 2019-09-24 Versitech Limited Amphiphilic dendrimers complexed with siRNA for treatment of cancer
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
JP7129420B6 (ja) 2017-03-30 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１阻害剤としてのイソキノリン
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
US20180290977A1 (en) 2017-03-30 2018-10-11 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
JP2020515579A (ja) 2017-03-30 2020-05-28 プロジェニティ， インコーポレイテッド 消化管疾病の生菌生物学的製剤による治療
CA3052492A1 (en) 2017-03-30 2018-10-04 F.Hoffmann-La Roche Ag Naphthyridines as inhibitors of hpk1
TWI871272B (zh) 2017-04-11 2025-02-01 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
US20230192839A1 (en) 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3615570A4 (en) 2017-04-25 2021-02-24 LBL Biotechnology Inc. USE OF IL-20 ANTAGONISTS FOR TREATMENT OF EYE DISEASES
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
US11447564B2 (en) 2017-04-26 2022-09-20 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
SG11201910183SA (en) 2017-05-04 2019-11-28 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
CN110913904A (zh) 2017-05-05 2020-03-24 美国安进公司 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
JP2020519647A (ja) 2017-05-12 2020-07-02 マヴァロン・セラピューティクス・リミテッド グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換複素環式化合物
EP3634403B1 (en) 2017-05-12 2025-06-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
AU2018288852B2 (en) 2017-06-21 2025-02-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
KR102714165B1 (ko) 2017-07-11 2024-10-10 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 작동자 항체 및 이의 용도
BR112020000679A2 (pt) 2017-07-13 2020-07-14 Massachusetts Institute Of Technology visando o complexo hdac2-sp3 para potencializar a função sináptica
SG11202000333UA (en) 2017-07-14 2020-02-27 Hoffmann La Roche Bicyclic ketone compounds and methods of use thereof
CN111372599A (zh) 2017-07-19 2020-07-03 奥克兰联合服务有限公司 细胞因子调节
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
MX2020000604A (es) 2017-07-21 2020-09-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
EP3658584A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
JP2020528418A (ja) 2017-07-26 2020-09-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
CA3073669A1 (en) 2017-08-22 2019-02-28 Cedars-Sinai Medical Center Compositions and methods for treating cancer
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
EP3676293A1 (en) 2017-08-30 2020-07-08 CytomX Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
EP3692061A1 (en) 2017-10-04 2020-08-12 Amgen Inc. Transthyretin immunoglobulin fusions
CA3078653A1 (en) 2017-10-11 2019-04-18 F. Hoffmann-La Roche Ag Bicyclic compounds for use as rip1 kinase inhibitors
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
KR20200064096A (ko) 2017-10-14 2020-06-05 싸이톰스 테라퓨틱스, 인크. 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법
US10336724B2 (en) 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3700567A4 (en) 2017-10-26 2021-09-29 The Regents of The University of California INHIBITION OF OXIDATION-SPECIFIC EPITOPIA TO TREAT REPERFUSION ISCHEMIC DAMAGE
IL312910A (en) 2017-10-27 2024-07-01 Univ New York Anti-galectin-9 antibodies and uses thereof
WO2019082020A1 (en) 2017-10-27 2019-05-02 Pfizer Inc. ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF
IL274071B2 (en) 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
EP3704132A4 (en) 2017-10-30 2021-07-28 Enterin, Inc. NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
CR20200168A (es) 2017-10-31 2020-07-12 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112020009275A2 (pt) 2017-11-15 2020-10-27 Semma Therapeutics, Inc. composições de fabricação de célula de ilhota e métodos de uso
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
GB2568526A (en) * 2017-11-20 2019-05-22 Rebio Tech Oy Composition
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
US20200281857A1 (en) 2017-11-22 2020-09-10 Dauntless 1, Inc. Therapeutic compound formulations
WO2019110139A1 (en) 2017-12-05 2019-06-13 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
WO2019114839A1 (zh) 2017-12-15 2019-06-20 泰伦基国际有限公司 一种预防或治疗骨关节炎的方法和药物
DK3723768T3 (da) 2017-12-15 2025-01-06 Univ Australian National Forbindelser til behandling og forebyggelse af patologier medieret af ekstracellulære histoner
EP3728310A1 (en) 2017-12-18 2020-10-28 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN111741767A (zh) 2017-12-19 2020-10-02 麻省理工学院 抗原-佐剂偶联剂和使用方法
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
JP2021507703A (ja) 2017-12-20 2021-02-25 ポセイダ セラピューティクス，インコーポレイティド Ｖｃａｒ組成物とその利用法
EP3732202A4 (en) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
EP3732203A4 (en) 2017-12-28 2021-12-15 Nanjing Legend Biotech Co., Ltd. ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
KR102741868B1 (ko) 2018-01-09 2024-12-11 돔페 파르마써티씨 에스.피.에이. 성장 인자 귀 제제
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
US12269804B2 (en) 2018-01-17 2025-04-08 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
MA51619A (fr) 2018-01-17 2021-04-14 Vertex Pharma Inhibiteurs de la protéine kinase dépendante de l'adn
US12121524B2 (en) 2018-01-17 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
JP7652566B2 (ja) 2018-01-24 2025-03-27 ジェネンテック， インコーポレイテッド 関節リウマチ（ｒａ）の処置のための診断方法及び治療方法
WO2019148020A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CR20200327A (es) 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
EP3746123A4 (en) 2018-02-01 2021-12-01 Memorial Sloan-Kettering Cancer Center ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE
BR112020016169A2 (pt) 2018-02-08 2020-12-15 Genentech, Inc. Moléculas de ligação ao antígeno biespecíficas, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, conjunto de ácidos nucleicos isolados, conjunto de vetores, conjunto de células hospedeiras, imunoconjugado, composição, uso da molécula de ligação, métodos para tratar ou retardar a progressão de um câncer, métodos para aperfeiçoar a função imune e kit
MX2020008291A (es) 2018-02-09 2020-09-25 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos.
CN112040976A (zh) 2018-02-09 2020-12-04 雀巢皮肤健康公司 奈莫利珠单抗对具有中至重度表皮脱落的异位性皮炎的治疗
TW202000201A (zh) 2018-02-20 2020-01-01 瑞士商赫孚孟拉羅股份公司 製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
MA51907A (fr) 2018-02-21 2021-05-26 Hoffmann La Roche Posologie pour un traitement avec des protéines de fusion il-22 fc
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CA3092635A1 (en) 2018-03-14 2019-09-19 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof
US11203646B2 (en) 2018-03-14 2021-12-21 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
KR20250160366A (ko) 2018-03-22 2025-11-12 서피스 온콜로지, 엘엘씨 항-il-27 항체 및 이의 용도
MX2020010301A (es) 2018-03-29 2020-10-20 Helsingin Yliopisto Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
AU2019243595A1 (en) 2018-03-30 2020-09-17 Amgen Inc. C-terminal antibody variants
CN111886254B (zh) 2018-03-30 2023-12-08 南京传奇生物科技有限公司 针对lag-3的单结构域抗体及其用途
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US20210163406A1 (en) 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
EP3774763A1 (en) 2018-04-06 2021-02-17 Zilentin Ag Bumetanide derivatives for the therapy of hyperhidrosis
JOP20200258A1 (ar) 2018-04-09 2020-10-11 Amgen Inc البروتينات الاندماجية لعامل تمايز النمو 15
SG11202009804RA (en) 2018-04-11 2020-11-27 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019197607A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Fc-engineered anti-human ige antibodies and methods of use
JP2021521219A (ja) 2018-04-18 2021-08-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｂｅｔ阻害剤およびプロテアソーム阻害剤を用いる併用療法
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
EP3788077A1 (en) 2018-05-02 2021-03-10 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
AU2019272575A1 (en) 2018-05-21 2020-12-10 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by NK cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
AU2019274655B2 (en) 2018-05-23 2023-03-09 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
JP7384835B2 (ja) 2018-05-23 2023-11-21 ファイザー・インク Ｃｄ３に特異的な抗体及びその使用
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
US20210196823A1 (en) 2018-06-08 2021-07-01 Pfizer Inc. Methods of Treating Metabolic Disease
WO2019241127A1 (en) 2018-06-11 2019-12-19 University Of Florida Research Foundation, Inc. Materials and methods for treating stress-related disorders and cancer
CN110577597B (zh) 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
CN112912110A (zh) 2018-06-12 2021-06-04 安吉克公司 抗体-寡核苷酸缀合物
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
DK3806855T5 (da) 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
AU2019288136A1 (en) 2018-06-18 2021-01-07 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
EP3807321A4 (en) 2018-06-18 2022-03-02 Anwita Biosciences, Inc. ANTI-MESOTHELIN CONSTRUCTIONS AND ASSOCIATED USES
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020005842A1 (en) 2018-06-25 2020-01-02 Dauntless 2, Inc. Membrane emulsification device with impeller for microsphere creation
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
KR20210028204A (ko) 2018-07-02 2021-03-11 암젠 인크 항-steap1 항원 결합 단백질
US10815240B2 (en) 2018-07-06 2020-10-27 Pfizer Inc. Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
US11130803B2 (en) 2018-07-11 2021-09-28 Scholar Rock, Inc. Isoform-selective TGFβ1 inhibitors and use thereof
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202012405A (zh) 2018-07-24 2020-04-01 瑞士商赫孚孟拉羅股份公司 萘啶化合物及其用途
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
CN118662499A (zh) 2018-08-08 2024-09-20 雪松-西奈医学中心 用于治疗癌症和自体免疫疾病的组合物和方法
US20210388089A1 (en) 2018-08-09 2021-12-16 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3833442A2 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antibodies that bind cd277 and uses thereof
CA3108275A1 (en) 2018-08-10 2020-02-13 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
MX2021001857A (es) 2018-08-17 2021-10-13 Genentech Inc Star Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.
MX2021002301A (es) 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN112805267B (zh) 2018-09-03 2024-03-08 豪夫迈·罗氏有限公司 用作tead调节剂的甲酰胺和磺酰胺衍生物
EP3846853A1 (en) 2018-09-04 2021-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal nanoparticles and use thereof against influenza virus
KR20210057124A (ko) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 용도
CN112689528B (zh) 2018-09-12 2024-05-14 基因泰克公司 嘧啶基-杂芳氧基-萘基化合物和使用方法
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
JP7486478B2 (ja) 2018-09-19 2024-05-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト スピロ環状２，３－ジヒドロ－７－アザインドール化合物およびその使用
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
MX2021003214A (es) 2018-09-19 2021-05-12 Genentech Inc Metodos terapeuticos y de diagnostico para el cancer de vejiga.
US20210353715A1 (en) 2018-09-20 2021-11-18 Mandalmed, Inc. Methods and compositions for preventing, treating, and reversing liver fibrosis
CN113365697B (zh) 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
WO2020065409A2 (en) 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
CN112771071A (zh) 2018-09-28 2021-05-07 麻省理工学院 胶原蛋白定位的免疫调节分子及其方法
JP7433304B2 (ja) 2018-09-30 2024-02-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト シンノリン化合物および癌などのｈｐｋ１依存性障害の治療
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
WO2020070333A1 (en) 2018-10-05 2020-04-09 Fondazione Telethon Ezrin inhibitors and uses thereof
MA53859A (fr) 2018-10-10 2022-01-19 Boehringer Ingelheim Int Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
EP3827016B1 (en) 2018-10-15 2025-12-03 Elixiron Immunotherapeutics (Hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
US11427591B2 (en) 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
MX2021004348A (es) 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
SG11202104010PA (en) 2018-10-23 2021-05-28 Scholar Rock Inc Rgmc-selective inhibitors and use thereof
ES3015004T3 (en) 2018-11-02 2025-04-28 Annexon Inc Compositions and methods for treating brain injury
JP2022512920A (ja) 2018-11-02 2022-02-07 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗ｃｄ１６６抗体およびその使用方法
KR20210124179A (ko) 2018-11-02 2021-10-14 베이징 브이디제이바이오 컴퍼니 리미티드 변형된 ctla4 및 이의 사용 방법
EP3880716A4 (en) 2018-11-13 2022-08-03 Compass Therapeutics LLC MULTISPECIFIC BINDING CONSTRUCTS DIRECTED AGAINST CHECKPOINT MOLECULES AND ASSOCIATED USES
EA202191058A1 (ru) 2018-11-16 2021-10-07 Мемориал Слоун Кеттеринг Кэнсер Сентр Антитела против муцина-16 и способы их применения
US12365670B2 (en) 2018-11-22 2025-07-22 Qilu Regor Therapeutics Inc. GLP-IR agonists and uses thereof
WO2020108423A1 (en) 2018-11-27 2020-06-04 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス，インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
KR20250021629A (ko) 2018-12-11 2025-02-13 큐32 바이오 인크. 보체　연관　질환을　위한　융합　단백질　작제물
AU2019399474A1 (en) 2018-12-13 2021-06-03 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
CN113498439A (zh) 2018-12-20 2021-10-12 波赛达治疗公司 纳米转座子组合物及使用方法
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
CN113423736B (zh) 2018-12-21 2023-07-18 普众发现医药科技(上海)有限公司 对muc18特异性的抗体
US11352445B2 (en) 2018-12-31 2022-06-07 Jecho Laboratories Inc. Method for preparing recombinant protein from bacterium and composition containing the same
EP3941919B1 (en) 2019-01-03 2025-12-24 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
KR20210113261A (ko) 2019-01-04 2021-09-15 리졸브 테라퓨틱스, 엘엘씨 뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
JP7324530B2 (ja) 2019-01-07 2023-08-10 鴻緒生物医葯科技（北京）有限公司 新型ポリペプチド及びその治療用途
CN111499747B (zh) 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
JP7585205B2 (ja) 2019-01-11 2024-11-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピロロトリアゾールケトン化合物及びその使用方法
BR112021013903A2 (pt) 2019-01-15 2021-09-21 Janssen Biotech, Inc. Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
CA3127452A1 (en) 2019-01-22 2020-07-30 Massachusetts Institute Of Technology In vitro human blood brain barrier
CN114144190B (zh) 2019-01-23 2025-08-08 纽约大学 对T细胞受体的δ1链具有特异性的抗体
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
US20220064278A1 (en) 2019-01-23 2022-03-03 Janssen Biotech, Inc. Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
MA54845A (fr) 2019-01-30 2021-09-29 Scholar Rock Inc Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
MX2021009761A (es) 2019-02-15 2021-12-15 Pfizer Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este.
US20220135663A1 (en) 2019-02-18 2022-05-05 Pfizer Inc. Method of treatment of Chronic Low Back Pain
AR118119A1 (es) 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
US20220275059A1 (en) 2019-02-20 2022-09-01 Harbour Antibodies Bv Antibodies
US11739078B2 (en) 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
CN113677372A (zh) 2019-02-26 2021-11-19 西托姆克斯治疗公司 可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法
PH12021552107A1 (en) 2019-03-01 2022-05-30 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
SG11202109514VA (en) 2019-03-08 2021-09-29 Massachusetts Inst Technology Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
EA202192505A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
WO2020198136A1 (en) 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
JP7607579B2 (ja) 2019-03-27 2024-12-27 ティガティーエックス， インコーポレイテッド 工学的に操作されたＩｇＡ抗体および使用方法
MX2021011464A (es) 2019-03-29 2021-10-22 Chugai Pharmaceutical Co Ltd Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CR20210501A (es) 2019-04-02 2021-11-02 Array Biopharma Inc Inhibidores de la proteína tirosina fosfatasa
PE20220143A1 (es) 2019-04-12 2022-01-27 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
CN113795274A (zh) 2019-05-10 2021-12-14 泰伦基国际有限公司 一种治疗肌萎缩侧索硬化的方法和药物
WO2020236985A1 (en) 2019-05-21 2020-11-26 President And Fellows Of Harvard College Endocrine differentiation-inducing molecule
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2020241816A1 (ja) 2019-05-31 2020-12-03 国立大学法人大阪大学 新規な消化器がん治療剤およびそのスクリーニング方法
EP3976099A1 (en) 2019-05-31 2022-04-06 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
BR112021024425A2 (pt) 2019-06-03 2022-01-18 Janssen Biotech Inc Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
JP7765972B2 (ja) 2019-06-11 2025-11-07 ジェネンテック， インコーポレイテッド キナゾリニル化合物及び使用方法
TWI874409B (zh) 2019-06-13 2025-03-01 美商安進公司 生物製品製造中基於生物量之自動灌注控制
US12448462B2 (en) 2019-06-14 2025-10-21 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1
EP3986917A1 (en) 2019-06-20 2022-04-27 CSPC Megalith Biopharmaceutical Co., Ltd. Modified il-2 proteins, peg conjugates, and uses thereof
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP3990452A1 (en) 2019-06-28 2022-05-04 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
KR20220032065A (ko) 2019-07-08 2022-03-15 암젠 인크 다중특이성 트랜스타이레틴 면역글로불린 융합
MY208387A (en) 2019-07-09 2025-05-05 Beijing Solobio Genetechnology Co Ltd Antibodies specifically recognizing pseudomonas pcrv and uses thereof
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
MX2022000988A (es) 2019-07-26 2022-05-03 Amgen Inc Proteinas de union a antigeno anti-il13.
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
EP4013788A1 (en) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
PE20220706A1 (es) 2019-08-13 2022-05-04 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CN114980901A (zh) 2019-08-30 2022-08-30 挪威西部创新股份有限公司 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
CN114450024A (zh) 2019-09-16 2022-05-06 表面肿瘤学公司 抗cd39抗体组合物和方法
WO2021055703A1 (en) 2019-09-20 2021-03-25 President And Fellows Of Harvard College Tough gel-based drug delivery compositions and methods thereof
US20220348687A1 (en) 2019-09-20 2022-11-03 Genentech, Inc. Dosing for anti-tryptase antibodies
JP2022548310A (ja) 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
JP2022549854A (ja) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
US11492622B2 (en) 2019-09-26 2022-11-08 Massachusetts Institute Of Technology MicroRNA-based logic gates and uses thereof
US11834659B2 (en) 2019-09-26 2023-12-05 Massachusetts Institute Of Technology Trans-activated functional RNA by strand displacement and uses thereof
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
JP7395723B2 (ja) 2019-10-02 2023-12-11 トルレモ・セラピューティクス・アクチェンゲゼルシャフト 複素環式誘導体、医薬組成物および癌の処置または寛解におけるそれらの使用
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
WO2021070885A1 (ja) 2019-10-11 2021-04-15 中外製薬株式会社 後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
US12410152B2 (en) 2019-10-16 2025-09-09 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
US20220378817A1 (en) 2019-10-23 2022-12-01 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
SMT202500220T1 (it) 2019-10-28 2025-07-22 Medimmune Ltd Formulazioni in polvere secca di anticorpi leganti linfopoietina stromale timica (tslp) e loro metodi d’uso
EP4058593A4 (en) 2019-11-12 2023-11-15 Foundation Medicine, Inc. METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
CA3155989A1 (en) 2019-11-13 2021-05-20 Jason Robert ZBIEG Therapeutic compounds and methods of use
EP4058485A1 (en) 2019-11-13 2022-09-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4061807A1 (en) 2019-11-19 2022-09-28 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
EP3831843A1 (en) 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
BR112022010599A2 (pt) 2019-12-10 2022-08-16 Pfizer Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
EP4077395A1 (en) 2019-12-20 2022-10-26 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
TWI845803B (zh) 2020-01-06 2024-06-21 美商法西尼克斯股份有限公司 抗ｃｃｒ８抗體及其用途
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4087649A1 (en) 2020-01-11 2022-11-16 Scholar Rock, Inc. Tgfbeta inhibitors and use thereof
CN115427447B (zh) 2020-01-17 2025-02-18 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
WO2021143906A1 (zh) 2020-01-17 2021-07-22 泰伦基国际有限公司 一种治疗神经损伤及其相关病症的方法
WO2021151079A1 (en) 2020-01-24 2021-07-29 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
JP2023512562A (ja) 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド 人工シナプス
JP7487970B2 (ja) 2020-02-06 2024-05-21 タレンゲン インターナショナル リミテッド 多発性硬化症を予防及び治療する方法並びに薬剤
US20230081922A1 (en) 2020-02-11 2023-03-16 Talengen International Limited Method and drug for treating viral pneumonia
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
US20240374599A1 (en) 2020-02-26 2024-11-14 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
JP7616698B2 (ja) 2020-02-26 2025-01-17 タレンゲン インターナショナル リミテッド 血圧異常症を予防及び治療する方法並びに薬剤
KR20220149588A (ko) 2020-03-04 2022-11-08 포세이다 테라퓨틱스, 인크. 대사성 간 장애의 치료를 위한 조성물 및 방법
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
AU2021234094A1 (en) 2020-03-10 2022-09-15 Tiziana Life Sciences Plc Compositions of IL-6/IL-6R antibodies and methods of use thereof
CN115243726B (zh) 2020-03-11 2025-07-15 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
EP4118107A1 (en) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
AU2021240028A1 (en) 2020-03-19 2022-09-15 Amgen Inc. Antibodies against mucin 17 and uses thereof
EP4107184A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
EP4107185A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
US20230174656A1 (en) 2020-03-23 2023-06-08 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
WO2021190561A1 (zh) 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗帕金森病的方法和药物
CN115666626A (zh) 2020-03-24 2023-01-31 泰伦基国际有限公司 一种治疗阿尔茨海默病的方法和药物
EP4122481B1 (en) 2020-03-24 2025-06-18 Talengen International Limited Method and medicine for treating huntington's disease
TW202143999A (zh) 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
EP4125896B1 (en) 2020-03-27 2025-05-07 Pfizer Inc. Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
BR112022019876A2 (pt) 2020-03-30 2022-11-22 Ecole Polytechnique Fed Lausanne Epfl Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US12410172B2 (en) 2020-04-08 2025-09-09 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2021211628A1 (en) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US11834485B2 (en) 2020-04-21 2023-12-05 Regeneron Pharmaceuticals, Inc. IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
US20230167198A1 (en) 2020-04-27 2023-06-01 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
EP4146688A1 (en) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Mask peptides and masked anti-ptk7 antibodies comprising such
WO2021227417A1 (zh) 2020-05-11 2021-11-18 泰伦基国际有限公司 一种治疗脊髓性肌萎缩症的方法和药物
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
DK4157832T3 (da) 2020-05-27 2024-09-23 Qilu Regor Therapeutics Inc Salt af krystalformer af glp-1r-agonister og anvendelser deraf
EP4157881A4 (en) 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
EP4161520A1 (en) 2020-06-05 2023-04-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Acvr1 (alk2) receptor inhibition to treat neurological diseases
RS65929B9 (sr) 2020-06-09 2025-02-28 Pfizer Spiro jedinjenja kao antagonisti receptora melanokortina 4 i njihova upotreba
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
EP4164693A1 (en) 2020-06-11 2023-04-19 Genentech, Inc. Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
EP4165071A4 (en) 2020-06-15 2024-07-17 Academia Sinica HUMANIZED AC2-FC FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
EP4168537A1 (en) 2020-06-17 2023-04-26 Tiziana Life Sciences PLC Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
WO2021259227A1 (zh) 2020-06-23 2021-12-30 江苏康缘药业股份有限公司 抗cd38抗体及其用途
US12472179B2 (en) 2020-06-25 2025-11-18 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
EP4171562A1 (en) 2020-06-25 2023-05-03 Tolremo Therapeutics AG Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
CN116113429A (zh) 2020-07-06 2023-05-12 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
WO2022023335A1 (en) 2020-07-30 2022-02-03 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal compositions and use thereof
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
IL300105A (en) 2020-07-31 2023-03-01 Vertex Pharma Pancreatic endocrine cell differentiation
AR123156A1 (es) 2020-08-06 2022-11-02 Qilu Regor Therapeutics Inc Agonistas de glp-1r y sus usos
CN116322765A (zh) 2020-08-14 2023-06-23 豪夫迈·罗氏有限公司 用于用奥瑞珠单抗治疗多发性硬化症的方法
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
EP4190911A4 (en) 2020-08-20 2024-03-13 Talengen International Limited METHOD AND MEDICINE FOR THE TREATMENT OF TUMORS
EP4203999A1 (en) 2020-08-26 2023-07-05 Scancell Limited Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
EP3964497A1 (en) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
EP4213877A1 (en) 2020-09-17 2023-07-26 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
MX2023003759A (es) 2020-10-02 2023-04-24 Genentech Inc Proceso para la preparacion de compuestos de biheteroarilo y formas cristalinas de estos.
EP4225794A1 (en) 2020-10-06 2023-08-16 Xencor, Inc. Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
ES3041328T3 (en) 2020-10-14 2025-11-11 Qilu Regor Therapeutics Inc Crystal forms of glp-1r agonists and uses thereof
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
CA3194868A1 (en) 2020-10-16 2022-04-21 Georg Winter Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
WO2022105788A1 (zh) 2020-11-17 2022-05-27 泰伦基国际有限公司 一种提高bdnf水平的方法和药物
CN116490200A (zh) 2020-11-17 2023-07-25 泰伦基国际有限公司 一种提高ngf水平的方法和药物
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
JP2024503000A (ja) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド 発現構築物およびその使用
JP2024503724A (ja) 2021-01-20 2024-01-26 オンコレスポンス，インク． 免疫調節抗体およびその使用
EP4288428A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Amides as cbl-b inhibitors
MX2023009135A (es) 2021-02-09 2023-08-16 Genentech Inc Compuestos de oxazepina tetraciclica y usos de estos.
EP4294834A2 (en) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Single domain antibodies that neutralize sars-cov-2
US20240060090A1 (en) 2021-02-23 2024-02-22 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
JP2024508818A (ja) 2021-02-24 2024-02-28 インシリコ メディシン アイピー リミテッド 疾患の処置のための類似体
US20240182921A1 (en) 2021-03-04 2024-06-06 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
AU2022232951B2 (en) 2021-03-10 2025-06-26 Immunowake Inc. Immunomodulatory molecules and uses thereof
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
TW202302143A (zh) 2021-03-12 2023-01-16 日商中外製藥股份有限公司 重症肌無力症之治療或預防用之醫藥組合物
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
WO2022204088A1 (en) 2021-03-22 2022-09-29 Massachusetts Institute Of Technology Multi-input mirna sensing with constitutive erns to regulate multi-output gene expression in mammalian cells
EP4313309A1 (en) 2021-03-22 2024-02-07 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20250161471A1 (en) 2021-04-03 2025-05-22 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
US20220411518A1 (en) 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
KR20230167092A (ko) 2021-04-07 2023-12-07 톨레모 테라퓨틱스 아게 헤테로사이클릭 유도체, 약학 조성물, 및 암의 치료 또는 개선에서의 그들의 용도
MX2023011873A (es) 2021-04-08 2023-10-17 Genentech Inc Compuestos de oxazepina y sus usos en el tratamiento del cancer.
WO2022221051A1 (en) 2021-04-11 2022-10-20 President And Fellows Of Harvard College Cardiomyocytes and compositions and methods for producing the same
WO2022223544A1 (en) 2021-04-19 2022-10-27 Centre National De La Recherche Scientifique (Cnrs) COMBINATION THERAPY OF NUCANT AND mTOR INHIBITORS FOR TREATING CANCER
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
US20240384006A1 (en) 2021-05-06 2024-11-21 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4334354A1 (en) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2022236134A1 (en) 2021-05-07 2022-11-10 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
MX2023013259A (es) 2021-05-13 2023-11-27 Alx Oncology Inc Terapias de combinacion para el tratamiento del cancer.
BR112023022474A2 (pt) 2021-05-14 2024-01-09 Claris Biotherapeutics Inc Composições de fator de crescimento para o tratamento de doença ocular
US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20240239875A1 (en) 2021-05-17 2024-07-18 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6
WO2022257979A1 (en) 2021-06-09 2022-12-15 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
EP4352101A1 (en) 2021-06-11 2024-04-17 Genentech, Inc. Method for treating chronic obstructive pulmonary disease with an st2 antagonist
US20240342187A1 (en) 2021-06-14 2024-10-17 Curtails Llc Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
WO2022271867A1 (en) 2021-06-23 2022-12-29 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
US20250011448A1 (en) 2021-07-08 2025-01-09 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN115812082A (zh) 2021-07-14 2023-03-17 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
JP2024527622A (ja) 2021-07-15 2024-07-25 オルスピム Ｉｌ－２３発現に関連する疾患を予防及び／または治療するための組成物及び方法
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
MX2024000567A (es) 2021-07-20 2024-01-29 Regeneron Pharma Agentes similares a butirofilina 2 para tratar trastornos inflamatorios.
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
US20240342188A1 (en) 2021-08-11 2024-10-17 Curtails Llc Use of NEP Inhibitors for the Treatment of Laminitis
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
WO2023028077A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. Sodium channel inhibitors and methods of designing same
US20230242652A1 (en) 2021-08-30 2023-08-03 Galderma Holding S.A. Treatments for atopic dermatitis
KR20240054335A (ko) 2021-08-31 2024-04-25 화이자 인코포레이티드 2-[(4-｛6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일｝피페리딘-1-일)메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카르복실산,1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태
AR126971A1 (es) 2021-09-03 2023-12-06 Univ Of Bern Composiciones y métodos para tratar el síndrome de qt largo
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023039276A1 (en) 2021-09-13 2023-03-16 Curtails Llc Use of ibat inhibitors and antimicrobials for the treatment of diseases
WO2023056368A1 (en) 2021-09-30 2023-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclic peptides as non-hormonal male contraceptive agents and methods of use thereof
JP2024536310A (ja) 2021-10-04 2024-10-04 ポセイダ セラピューティクス，インコーポレイティド トランスポゾン組成物及びその使用方法
US20240392262A1 (en) 2021-10-04 2024-11-28 Poseida Therapeutics, Inc. Transposase and uses thereof
CA3234693A1 (en) 2021-10-15 2023-04-20 Tango Therapeutics, Inc. Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
KR20240095331A (ko) 2021-11-05 2024-06-25 제넨테크, 인크. C-cbl에 비해 선택적인 cbl-b 억제제로서의 락탐
AU2022383057A1 (en) 2021-11-05 2024-05-16 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
TW202440647A (zh) 2021-11-19 2024-10-16 英商米羅比奧有限公司 經工程改造之pd-1抗體及其用途
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
CA3238936A1 (en) 2021-11-24 2023-06-01 Wayne A. Marasco Antibodies against ctla-4 and methods of use thereof
EP4436969A2 (en) 2021-11-24 2024-10-02 Genentech, Inc. Bicyclic therapeutic compounds and methods of use in the treatment of cancer
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
AU2022402913A1 (en) 2021-12-03 2024-06-13 Tango Therapeutics, Inc. Novel hdac inhibitors and therapeutic use thereof
EP4444708B1 (en) 2021-12-06 2025-07-30 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
WO2023103788A1 (zh) 2021-12-06 2023-06-15 北京三诺佳邑生物技术有限责任公司 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
US20250011304A1 (en) 2021-12-08 2025-01-09 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
US20250051755A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023111817A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.
CN119212728A (zh) 2022-02-04 2024-12-27 丹娜-法伯癌症研究院 用于处理神经病的组合物和方法
US20250171809A1 (en) 2022-02-23 2025-05-29 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
CA3254549A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. BISPECIFIC ANTIBODY FUSION MOLECULES AND THEIR METHODS OF USE
CA3255847A1 (en) 2022-04-06 2023-10-12 Gilead Sciences, Inc. MODIFIED CD200R ANTIBODIES AND THEIR USES
EP4511013A1 (en) 2022-04-19 2025-02-26 Philera New Zealand Ltd. Treatment of brain copper disorders
WO2023203172A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
US20250289903A1 (en) 2022-04-29 2025-09-18 Purinnomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
EP4526309A1 (en) 2022-05-19 2025-03-26 Genentech, Inc. Aza-tetracyclic oxazepine compounds and uses thereof
WO2023228023A1 (en) 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230128A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
KR20250020474A (ko) 2022-06-03 2025-02-11 제나스 바이오파마, 인코포레이티드 IgG4-관련 질환을 치료하기 위한 방법 및 조성물
WO2023243689A1 (ja) 2022-06-16 2023-12-21 国立大学法人大阪大学 新規な炎症性疾患治療剤およびそのスクリーニング方法
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
EP4558523A1 (en) 2022-07-19 2025-05-28 Biolegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
EP4558528A1 (en) 2022-07-22 2025-05-28 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
EP4568990A1 (en) 2022-08-11 2025-06-18 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use
KR20250099103A (ko) 2022-08-15 2025-07-01 다나-파버 캔서 인스티튜트 인크. Cldn4에 대한 항체 및 이의 사용 방법
CN119855829A (zh) 2022-08-15 2025-04-18 丹娜-法伯癌症研究院 针对msln的抗体及其使用方法
CN119968395A (zh) 2022-08-18 2025-05-09 百进生物科技公司 抗axl抗体、其抗原结合片段及其制备和使用方法
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome
IL319323A (en) 2022-09-02 2025-05-01 Galderma Holding SA Treatments for prurigo nodularis
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
WO2024076995A1 (en) 2022-10-03 2024-04-11 Insigna Inc. Compositions for non-surgical prevention of boar taint and aggressive behavior
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
KR20250084918A (ko) 2022-10-18 2025-06-11 가부시키가이샤 에누비 켄코우겡큐쇼 항체, 핵산, 세포 및 의약
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
EP4605076A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
EP4605399A1 (en) 2022-10-19 2025-08-27 Genentech Inc. Oxazepine compounds comprising a 6-aza moiety and uses thereof
JP2025535386A (ja) 2022-10-20 2025-10-24 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 ＴＲＡＩＬまたはＦａｓＬに特異的に結合する抗体の組み合わせおよび二重特異性抗体
IL320152A (en) 2022-10-21 2025-06-01 Novimmune Sa Bispecific antibodies against PD-L1 and CD28 for immune checkpoint-dependent T cell activation
JP2025537112A (ja) 2022-11-02 2025-11-14 ソネット バイオセラピューティクス，インコーポレイテッド 癌の治療方法において使用するための組換えｉｌ－１２アルブミン結合ドメイン融合タンパク質
JP2025537179A (ja) 2022-11-04 2025-11-14 泰▲倫▼基国▲際▼有限公司 ユビキチンプロテアソーム系及びオートファジーリソソーム系による病理学的タンパク質の除去を促進する方法及び薬剤
KR20250096849A (ko) 2022-11-04 2025-06-27 탈렌젠 인터내셔널 리미티드 병리학적 tdp-43 단백질의 분해를 촉진하는 방법 및 약물
EP4630537A1 (en) 2022-12-07 2025-10-15 Fondazione Matilde Tettamanti e Menotti de Marchi Onlus Methods for generating genetically modified cytokine induced killer (cik) cells
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
EP4665392A2 (en) 2023-02-14 2025-12-24 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
CN121100184A (zh) 2023-02-21 2025-12-09 波西达治疗公司 Aav piggybac转座子多核苷酸组合物及其使用方法
EP4669746A1 (en) 2023-02-21 2025-12-31 Poseida Therapeutics, Inc. COMPOSITIONS AND GENOMIC EDITING PROCESSES
AU2024224961A1 (en) 2023-02-21 2025-09-11 Joint-Stock Company "Generium" Pharmaceutical composition and method for the prophylaxis and treatment of a lysosomal enzyme deficiency in a subject with mucopolysaccharidosis type ii
IL322767A (en) 2023-02-21 2025-10-01 Poseida Therapeutics Inc Genome editing vehicles and methods
WO2024184403A2 (en) 2023-03-06 2024-09-12 Snipr Biome Aps Targeting cells in stressed growing conditions
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
GB202303531D0 (en) 2023-03-10 2023-04-26 Fusion Antibodies Plc Antibodies and uses thereof
WO2024204671A1 (ja) 2023-03-31 2024-10-03 国立大学法人大阪大学 敗血症患者の予後を予測するためのバイオマーカーおよびその使用
KR20250167667A (ko) 2023-04-05 2025-12-01 포세이다 테라퓨틱스, 인크. 트랜스포사제 및 이의 용도
AU2024243923A1 (en) 2023-04-05 2025-11-13 Poseida Therapeutics, Inc. Chimeric transposases and uses thereof
KR20250167670A (ko) 2023-04-05 2025-12-01 포세이다 테라퓨틱스, 인크. 초극소 역위 말단 반복(itr) 서열 및 그의 용도
CN121195065A (zh) 2023-04-05 2025-12-23 波西达治疗公司 转座酶多核苷酸及其用途
AU2024254989A1 (en) 2023-04-12 2025-08-21 Strand Therapeutics Inc. Synthetic circuits and uses thereof
WO2024216164A1 (en) 2023-04-13 2024-10-17 Tango Therapeutics, Inc. N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer
KR20250173550A (ko) 2023-04-24 2025-12-10 제나스 바이오파마, 인코포레이티드 자가면역 용혈성 빈혈(aiha) 치료를 위한 방법 및 조성물
TW202448456A (zh) 2023-05-09 2024-12-16 美商建南德克公司 作為對ｃ－ｃｂｌ具選擇性之ｃｂｌ－ｂ抑制劑的６－經取代－３－苯基－異吲哚啉－１－酮類
WO2024233804A1 (en) 2023-05-10 2024-11-14 Poseida Therapeutics, Inc. Transposases and uses thereof
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
CN121152803A (zh) 2023-05-25 2025-12-16 百进公司 Ceacam6结合抗体和其抗原结合片段
WO2024251936A1 (en) 2023-06-07 2024-12-12 South East Technological University Composition comprising a combination of a corticosteroid and a flavonoid for use in treating eye-related diseases
CN121311467A (zh) 2023-06-09 2026-01-09 辉瑞大药厂 N-(甲氧羰基)-3-甲基-l-缬氨酰基-(4r)-n-{(1s)-1-氰基-2-[(3s)-2-氧代吡咯烷-3-基]乙基}-4-(三氟甲基)-l-脯氨酰胺及其溶剂化物的固体形式
GB202310227D0 (en) 2023-07-04 2023-08-16 Snipr Biome Aps Production & secretion of auxin-like molecules in bacteria
AU2024287304A1 (en) 2023-07-11 2025-12-04 F. Hoffmann-La Roche Ag Compositions and methods for treating multiple sclerosis
WO2025024559A1 (en) 2023-07-24 2025-01-30 Strand Therapeutics Inc. Rna-based synthetic circuit for producing engineered immune cells for an extracorporeal cell therapy
WO2025021790A2 (en) 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2025024704A1 (en) 2023-07-25 2025-01-30 Strand Therapeutics Inc. Polynucleotides comprising a micro rna detargeting sensor and uses thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
AU2024322991A1 (en) 2023-08-09 2026-01-08 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025040546A1 (en) 2023-08-18 2025-02-27 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025064507A1 (en) 2023-09-19 2025-03-27 Poseida Therapeutics, Inc. Compositions and methods for integration of viral vectors
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
TW202530264A (zh) 2023-10-02 2025-08-01 美商澤納仕生物製藥股份有限公司 用於治療多發性硬化症之方法及組合物
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2025085512A1 (en) 2023-10-16 2025-04-24 Evolveimmune Therapeutics, Inc. Combination therapies with ulbp2 targeting antibodies for treating cancers
WO2025099561A1 (en) 2023-11-07 2025-05-15 Pfizer Inc. Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2025104236A1 (en) 2023-11-15 2025-05-22 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025111582A1 (en) 2023-11-22 2025-05-30 Genentech, Inc. Aza-tetracyclic oxazepine inhibitors of kras-g12d
WO2025114357A1 (en) 2023-11-28 2025-06-05 Novimmune Sa Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
WO2025122609A1 (en) 2023-12-04 2025-06-12 Strand Therapeutics Inc. Circular rna synthesis
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
WO2025122885A1 (en) 2023-12-08 2025-06-12 Absci Corporation Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
WO2025144974A1 (en) 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
US20250223356A1 (en) 2024-01-08 2025-07-10 Zenas Biopharma, Inc. Methods and compositions for treating relapsing multiple sclerosis
WO2025153942A1 (en) 2024-01-16 2025-07-24 Pfizer Inc. Benzodiazepine pyrazolo carboxamides as n-protein inhibitors
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a
WO2025155844A1 (en) 2024-01-17 2025-07-24 Zenas Biopharma, Inc. Methods and compositions for treating systemic lupus erythematous (sle)
WO2025194134A1 (en) 2024-03-15 2025-09-18 Genentech, Inc. Linearly substituted oxazepin-5-one kras-g12d inhibitors
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025224648A1 (en) 2024-04-26 2025-10-30 Pfizer Inc. Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185625A (en) * 1961-11-08 1965-05-25 Brown Ethan Allan Injectionable substances
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet

Also Published As

Publication number Publication date
DE2051580A1 (de) 1971-05-06
GB1325209A (en) 1973-08-01
DE2051580C3 (de) 1981-04-02
JPS5017525B1 (Direct) 1975-06-21
US3773919A (en) 1973-11-20
FR2070153A1 (Direct) 1971-09-10
FR2070153B1 (Direct) 1975-01-10
DE2051580B2 (de) 1980-07-10

Similar Documents

Publication Publication Date Title
CA982479A (en) Polylactide-drug mixtures
CA918701A (en) Connecteur sous-marin
AU1550770A (en) Jackstrip
AU1707970A (en) Rotocyclone
AU1812170A (en) 14b-hydroxy-15-acyloxy-cardenolides
AU4286968A (en) Stumplifter
AU1646670A (en) d-18-METHYL-17d-ALKYNYL-4-OESTREN-17b-OLS
AU446111B2 (en) Electromagmet
AU1739070A (en) Quinoxaline-din-oxide-hydroxy-lactone
CA813393A (en) Aminoplast-phenoplast mixtures
CA810663A (en) Stable starch-cyanamide mixtures
AU449730B2 (en) Vanadiumnitride or mixtures therefrom
AU437024B2 (en) Cyanalkylaminotriazines
AU449377B2 (en) Phenylthiobenzylamines
AU441776B2 (en) 4-halo-sydnonimines
AU441340B2 (en) N-arylureas
AU441248B2 (en) Magnetodiodes
AU441216B2 (en) 13-aminomethylsteroids
AU440985B2 (en) Start-stop-oscillator
AU440104B2 (en) Slip-hook
AU438523B2 (en) N- phenacylcarbamates
AU437643B2 (en) -cyanoalkylcarbamylbenzimidazoles
AU437508B2 (en) Bornanocarbozamides
AU443942B2 (en) Traizaspyrodecandithiones
AU430140B2 (en) Aminobenzocycloalkylnitriles